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Molecular Dynamics Associated With
Chronic Pain in the PNS and Spinal
Cord
Allison M. Barry †, Julia R. Sondermann, Jan-Hendrik Sondermann, David Gomez-Varela*
and Manuela Schmidt*
Max-Planck Institute of Experimental Medicine, Somatosensory Signaling and Systems Biology Group, Goettingen, Germany
To obtain a thorough understanding of chronic pain, large-scale molecular mapping of
the pain axis at the protein level is necessary, but has not yet been achieved. We applied
quantitative proteome profiling to build a comprehensive protein compendium of three
regions of the pain neuraxis in mice: the sciatic nerve (SN), the dorsal root ganglia (DRG),
and the spinal cord (SC). Furthermore, extensive bioinformatics analysis enabled us to
reveal unique protein subsets which are specifically enriched in the peripheral nervous
system (PNS) and SC. The immense value of these datasets for the scientific community
is highlighted by validation experiments, where we monitored protein network dynamics
during neuropathic pain. Here, we resolved profound region-specific differences and
distinct changes of PNS-enriched proteins under pathological conditions. Overall, we
provide a unique and validated systems biology proteome resource (summarized in our
online database painproteome.em.mpg.de), which facilitates mechanistic insights into
somatosensory biology and chronic pain—a prerequisite for the identification of novel
therapeutic targets.
Keywords: chronic pain, DIA-MS, proteomics, systems biology, neuropathic pain, dorsal root ganglia, sciatic
nerve, spinal cord
INTRODUCTION
Chronic pain is a complex maladaptive disease. It has a high incidence and is a major cause of
long term disability (Breivik, 2013). Despite prominent scientific advances, our knowledge of the
mechanistic underpinnings of chronic pain syndromes remains unsatisfactory (Costigan et al.,
2009; Price and Gold, 2017). Effective treatment faces major challenges, largely arising from the
fact that therapeutic interventions target widely expressed molecules in multiple tissues, including
the central nervous system (Borsook et al., 2014; Price and Gold, 2017). Their modulation is
accompanied by severe side effects (Patapoutian et al., 2009; Price and Gold, 2017). Central side
effects can be attenuated by selectively targeting the PNS (i.e., afferent fibers, DRG), e.g., by local
injections (intranerval, intraganglionic, and epidural). This facilitates effective and safer treatment
options (Puljak et al., 2009; Liem et al., 2013; Krames, 2014; Berta et al., 2017b). Interestingly,
several studies have demonstrated a crucial role of primary afferent input for the maintenance of
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chronic pain, e.g., neuropathic pain (Sapunar et al., 2012; Liem
et al., 2013; Haroutounian et al., 2014; Krames, 2014), and
phantom limb pain (Vaso et al., 2014). While the existence of a
peripheral “pain” generator is becoming increasingly accepted,
associated changes in molecules and protein networks remain to
be fully elucidated (Costigan, 2012; Borsook et al., 2014).
During the past decade, enormous progress has been made
toward the identification of molecules implicated in chronic
pain. These studies have yielded important insights into genetic
variants (Diatchenko et al., 2007, 2013; van Hecke et al., 2015;
Zorina-Lichtenwalter et al., 2016; Parisien et al., 2017; Peng
et al., 2017) and transcriptome alterations (Grace et al., 2012;
Antunes-Martins et al., 2013; Simonetti et al., 2013; Jeong
et al., 2016) relevant for chronic pain. Yet, the interpretation
of these results is often not straightforward. In particular,
genome/transcriptome-based techniques suffer from a limited
correspondence between genomic/transcriptomic and proteomic
content (Schwanhausser et al., 2011; Sharma et al., 2015; Liu et al.,
2016).
As proteins are the functional building blocks of cells, they
strongly influence the status-quo of a cell, tissue or even
organism. Several proteome studies have thus been conducted
on chronic pain (Huang et al., 2008; Olausson et al., 2012,
2015; Sui et al., 2014; Vacca et al., 2014). We are still lacking,
however, an integrated systems-level view of protein network
organization and dynamics (Alberts, 1998; Rouwette et al., 2015)
in the somatosensory system. According to emerging network
medicine efforts, the identification of cellular networks and in
particular, distinct hubs of diseasemodules within these networks
(Chapman et al., 2008; Barabási et al., 2011; Antunes-Martins
et al., 2013; Borsook and Kalso, 2013; Chen et al., 2015), may hold
great potential for diagnosis, patient stratification, and design of
selective therapeutic interventions for chronic pain conditions
(Gereau et al., 2014; Baron et al., 2017; Price and Gold, 2017).
We have previously demonstrated the potential of an
emerging mass spectrometry-based proteomic technique (so-
called data-independent acquisition mass spectrometry, DIA-
MS) to reproducibly profile proteome changes in DRG of two
mouse models of chronic pain (Rouwette et al., 2016). Here we
considerably extended our approach to build a comprehensive
protein compendium (>5000 proteins in total) of three regions
at the beginning of the pain neuraxis: the sciatic nerve (SN),
the DRG, and the spinal cord (SC). We compared this data to
tissue proteomes of the central nervous system which enabled
us to define “region-enriched” proteomes. The immense value of
these defined region-enriched proteomes becomes apparent by
(i) the inclusion of many proteins known to be involved in pain
in mice and humans, (ii) the identification of uncharacterized
proteins in a tissue-dependent manner, and (iii) the results
of our validation experiments resolving profound differences
among analyzed tissues and distinct modulations of PNS-
enriched proteins during neuropathic pain. Taken together,
our findings provide the scientific community with a unique
protein-centric systems biology framework for studying the
PNS and SC in normal and pathological states. All presented
data are summarized in a freely accessible online database at
painproteome.em.mpg.de.
METHODS
All experiments were performed by observing standard
institutional biosecurity and institutional safety procedures. All
workplaces and involved personnel were approved for biosafety
level 1 (BSL-1) procedures.
Mice and Behavior
Adult C57Bl/6J male mice (6–8 weeks old at the time of
surgery) were bred in-house and kept in a temperature-
and humidity-controlled environment under a 12 h light/dark
cycle with food and water provided ad libitum. All animal
experiments were approved and carried out in compliance with
institutional guidelines and guidelines of the Landesamt für
Verbraucherschutz und Lebensmittelsicherheit of Lower Saxony,
Germany (3392-42502-04-13/1077).
The spared nerve injury (SNI) paradigm was induced
according to standard protocols as described previously
(Decosterd and Woolf, 2000; Minett et al., 2013; Rouwette et al.,
2016). Mice were anesthetized with isoflurane (4% induction,
1.8% maintenance) and the SN and its branches, the common
peroneal, tibial, and sural nerves, were exposed. Common
peroneal and tibial nerves were ligated with a 6.0 silk suture
(Braun) and transected distal to the ligation, removing 2–3mm
of each nerve. Care was taken to avoid damaging the sural
nerve. Sham surgery was performed in a similar manner without
ligating and transecting the nerves. The surgical procedure lasted
approximately 15min. Analgesia during surgery was achieved
by Buprenorphine (0.07 mg/kg body weight; Guarnieri et al.,
2012). Postsurgical analgesia was achieved by subcutaneous
injection of Carprofen (5 mg/kg body weight) for up to 3
days, as necessary. Mechanical sensitivity was assessed 2 days
before and 26 days after surgery with a dynamic plantar
aesthesiometer (Ugo Basile), as described (Rouwette et al., 2016).
Behavioral tests were performed in the light phase in a blinded
manner. Mice with neuropathic pain, however, could be easily
identified upon the first measurements due to the pronounced
mechanical hypersensitivity. All 12 mice which underwent
SNI surgery exhibited evident mechanical hypersensitivity
(manifested as reduced withdrawal latencies) but were otherwise
indistinguishable from Sham surgery mice. None of the 12
mice which underwent Sham surgery exhibited mechanical
hypersensitivity. All mice were euthanized with CO2 for tissue
collection 28 days after surgery.
The following tissues were isolated after Sham surgery or SNI:
ipsilateral sciatic nerve, ipsilateral DRG (L3-L5), ipsilateral SC
(L3-L5; a reliable and consistent separation of dorsal and ventral
horn was technically not feasible), amygdala, anterior cingulate
cortex, prefrontal cortex, and cerebellum.
Protein Isolation
Tissues were isolated immediately after CO2 euthanization,
snap-frozen in liquid nitrogen, and stored at −80◦C. Tissue
from 4 mice were pooled to obtain 3 replicates per tissue and
per condition. Protein isolation was performed as described
previously (Bruderer et al., 2017b). In brief, the frozen tissue was
homogenized in 4% SDS lysis buffer (4% SDS in 100mM Tris,
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10mM DTT, 5% glycerol, complete protease inhibitor cocktail
(Roche), pH 7.5). Following, the homogenate was incubated at
70◦C for 10min. To remove cell debris, the homogenate was
centrifuged at 10,000 × g for 5min at room temperature. The
supernatant corresponds to the whole cell lysates. Subsequently,
proteins were precipitated by the addition of 5 × volume pre-
chilled acetone (Roth) and incubated for 2 h at −20◦C. The
protein precipitate was centrifuged at 14,000 × g for 30min, the
pellet washed with ice cold 80% ethanol (AppliedChem), and
centrifuged again at 14,000 × g for 30min. The proteins were
air-dried, re-suspended in 2% SDS lysis buffer, and ultimately
analyzed by DIA-MS.
To generate the spectral library, i.e., a compendium of
all detectable peptides and their physicochemical information
necessary to uniquely identify peptides in subsequent DIA-MS
experiments, membrane and cytosolic fractions of the whole
cell lysate were prepared for one replicate per condition of
each tissue. To this end, the whole cell lysate was subjected to
ultracentrifugation at 100,000 × g for 1 h at 18◦C (TLA 100.3
rotor, Beckman Coulter). The supernatant (cytosolic fraction)
and the dissolved pellet (membrane fraction; in 2% SDS lysis
buffer) were subjected to protein precipitation as described
above.
Pan-Mouse Library Generation, DIA-MS,
and Data Analysis
Sample preparation, pan-mouse spectral library generation, and
DIA-MS were performed by Biognosys (Zurich, Switzerland)
as previously reported (Bruderer et al., 2015, 2017b; Rouwette
et al., 2016). Data were analyzed with Spectronaut Pulsar
(Biognosys) with precursor and protein FDR set at 0.01. Further
analyses were performed with R (https://www.r-project.org/).
Upon publication, all DIA-MS data, and the pan-mouse library
will be publicly available in the Peptide Atlas (www.peptideatlas.
org) and in our database painproteome.em.mpg.de.
Examining Reproducibility
To examine reproducibility across samples, regression analyses
were performed. Protein intensities were calculated per protein
per replicate, as a mean intensity across peptides. Pearson’s
correlation coefficients were subsequently calculated for samples
within each tissue, and kernel density estimates were used to
visualize sample distribution. Initial analyses were performed
with R, and subsequent plotting done with Python (Python
Software Foundation, https://www.python.org/). Unsupervised
hierarchical clustering was performed in Perseus v1.5.6.0
(Tyanova et al., 2016). The clustering was done with Euclidean
distances and average linkage on mean protein intensities
(per replicate), which had been log2 transformed and z-score
normalized. For visualization purposes (i.e., to help find proteins
showing similar expression), row clusters with an arbitrary
chosen distance threshold of 3.4 were presented in different
colors.
Establishing Tissue Proteomes
For each control (Sham) tissue, peptide intensities were
combined across all three replicates for a given protein identifier.
Mean intensity, standard deviation, and the number of peptides
were calculated. A positive protein detection refers to at least
one peptide in all three Sham replicates. We opted to include
all proteins meeting these criteria (i.e., including proteins only
identified by a single peptide across all three Sham replicates) to
be able (i) to provide the most comprehensive analysis of tissue
proteomes and (ii) to perform the most stringent comparisons
across tissues possible (see below for the definition of tissue-
enriched proteomes). To prevent redundancy in our protein list,
as well as facilitate literature comparisons (described below), only
protein identifiers corresponding to reviewed Uniprot entries
(http://www.uniprot.org) were used for subsequent analysis.
Additionally, detected keratin contamination was removed from
the analysis. This analysis was repeated using a spectral library
designed in silico from the mouse brain proteome data published
by Sharma and colleagues (Sharma et al., 2015).
Quantification of Changes in Protein Abundance
Upon SNI
To calculate expression changes in the SNI model, log2 intensity
ratios were first calculated between SNI and Sham tissues at a
peptide level. For each peptide, three ratios were calculated: SNI
Replicate 1/Sham Replicate 1, SNI Replicate 2/Sham Replicate
2, SNI Replicate 3/Sham Replicate 3. Hence, peptides were
only considered if they are detected across all three Sham
replicates and all three SNI replicates. Mean log2 ratios were
subsequently calculated for each protein ID, and one-sample
t-tests were performed. After filtering for reviewed Uniprot
IDs, p-values were adjusted using the Benjamini-Hochberg (BH)
procedure (R: p.adjust, method = “BH”). Regulated proteins
were defined as having a BH-adjusted p-value q < 0.05. If
the regulation of a protein could only be established based
on a single peptide across all six samples, it was considered
a “low confidence regulated hit” and is highlighted as such
in Supplementary Table 8 (according to latest considerations
regarding the quantitation based on single-peptide hits, please
see tutorial at http://www.mcponline.org/site/misc/ParisReport_
Final.xhtml). In keeping with the Sham data, only reviewed
Uniprot entries were considered and keratin contaminations
were removed.
Comparative Proteome Data Analysis
Establishing a PNS-Enriched Proteome
In the interest of establishing a PNS-enriched proteome, DRG
and SN data were compared to four brain tissues (ACC, AMY,
PFC, and CER). A protein was considered to be PNS-enriched if
either criteria was met: (A) protein was detected in DRG and/or
SN but none of the brain tissues, or (B) 10-fold enrichment (one
order of magnitude) in at least one PNS tissue compared to brain
regions. To calculate the latter, protein abundance was compared
between each PNS-tissue and the maximum abundance detected
in a brain region. A 1-tailed Welch’s t-test was used to determine
significance (p < 0.05). Only proteins which were more than 10-
fold enriched with a p < 0.05 were considered PNS-enriched
for further analysis. To strengthen our confidence in the PNS-
enriched proteome, we then compared this initial PNS-enriched
list to data analyzed using the in silico library designed from
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the mouse brain proteome published by Sharma and colleagues
(Sharma et al., 2015). Any protein which was detected in a brain
tissue of this secondary analysis was removed from the PNS-
enriched list, unless it met our 10-fold enrichment criteria. Again,
proteins identified by a single peptide across replicates were
included to enable the most stringent tissue comparison possible.
Establishing an SC-Enriched Proteome
An SC-enriched proteome was produced by mirroring the
aforementioned criteria: non-detected in any brain region or 10-
fold enriched (p < 0.05), with subsequent comparison to data
analyzed using the in silico library designed from themouse brain
proteome data published by Sharma and colleagues (Sharma
et al., 2015).
Published Literature Comparisons
To assess the quality of our datasets, as well as the translational
applications, our data were compared to relevant previously
published genomic, transcriptomic, and proteomic datasets.
For each comparison, identifiers were uploaded to Uniprot
and converted to reviewed mouse Uniprot identifiers.
This conversion provided a framework for genomic and
transcriptomic, as well as human data to be matched to our
mouse-generated proteome. Of note, the conversion to reviewed
Uniprot identifiers from previously published data resulted
in a loss of some identifiers, occasionally reducing the total
number of proteins used for the comparison. Even so, this
standardization allowed for a comparison not otherwise possible.
Percentage overlap was calculated between these lists and our
datasets (e.g., all proteins, PNS-enriched, SC-enriched, proteins
regulated in SNI/Sham, etc.). For comparison to the Human
Protein Atlas (Uhlen et al., 2015; Thul et al., 2017), data were
accessed in July 2017, corresponding to Protein Atlas version
16.1. Both “approved” and “supported” proteins at expression
scores of “low,” “medium,” and “high” were included. Full
details about the annotations can be found here: https://www.
proteinatlas.org/about/assays+annotation. In essence, reliably
detected proteins were examined across all tissues. Proteins
with uncertain reliability scores and those “not detected” were
excluded for a given tissue. All tissues were compiled for the
analysis, as no data from PNS tissue was included in the Atlas.
Identifiers were then uploaded to Uniprot and converted, as
described above.
Retrospective Analysis of Two Chronic Pain Models
Previously, our group has reported changes in the DRG
membrane proteome upon SNI and inflammatory pain induced
by CFA injection (Rouwette et al., 2016). These data were
reanalyzed with our updated generated pan-mouse library.
Proteins regulated in either pain model were subsequently
compared to determine commonly-regulated proteins.
Ingenuity Pathway Analysis (IPA®)
Protein lists (per tissue: Sham and SNI/Sham, PNS-enriched, SC-
enriched) were uploaded to IPA R© (Qiagen) for further analysis.
For SNI/Sham data, only significantly regulated proteins q< 0.05
(BH-adjusted p-value) were considered.
Gene Ontology Analysis
Protein lists (per tissue: Sham and SNI/Sham, PNS-enriched,
SC-enriched) were uploaded to the web interfaces DAVID
(david.ncifcrf.gov; Huang da et al., 2009) and STRING (string-
db.org; Franceschini et al., 2013). We reported only significant
enrichments (FDR < 0.05) in cellular component (CC) or
biological process (BP).
RESULTS
Standardized Proteome Profiling of
Tissues Relevant for Pain
The goal of our study was twofold. On one hand, we aimed
to comprehensively define the adult mouse proteome of the
SN, DRG, and SC. On the other hand, we envisioned using
this information to enable the trustful monitoring of proteome
alterations during a chronic pain condition. To this end, we
chose the widely employed spared-nerve-injury (SNI)-model of
neuropathic pain (Decosterd and Woolf, 2000) and performed a
comparison to Sham-operated control mice (please see Methods
for details on mice).
Our workflow is outlined in Figure 1, and ranges from the
induction of neuropathic pain, via DIA-MS to an in-depth data
and pathway analysis.
Initially, we focused on Sham-operated mice as controls to
define region-resolved proteomes (Figure 1 left). We prepared
lysates of the SN, DRG, and SC. For the sake of comparative
analysis between the PNS (SN and DRG) and CNS, we
additionally prepared lysates of four major brain regions: the
prefrontal cortex (PFC), the anterior cingulate cortex (ACC), the
amygdala (AMY), and the cerebellum (CER). The first three CNS
regions were chosen based on their implication in chronic pain
states. The CER was chosen based on a recent study showing that
the DRG transcriptome resembled the cerebellummore than any
other brain region (Parisien et al., 2017).
Using mass spectrometry, we first generated a spectral
library according to previously established procedures
(Rouwette et al., 2016; Figure 1). Next, we assembled a
pan-mouse peptide spectral library (pan-mouse library) by
combining individual tissue libraries obtained in this study
with our previously published libraries (Rouwette et al., 2016;
Bruderer et al., 2017a,b). Taken together, this pan-mouse library
contains peptides corresponding to 6205 proteins (complete
list: Supplementary Table 1). These include 3008 proteins
predicted to be localized to the membrane according to gene
ontology (GO) analysis for cellular compartment, GO_CC (BH-
corrected p-value: 5,2 × 10−173) using the web interface DAVID
(Huang da et al., 2009). Among these, 254 are annotated to be
involved in ion transport (GO analysis for biological process,
GO_BP; BH-corrected p-value: 1,8 × 10−7) including ion
channels and receptors with prominent functions in nociceptive
processing, e.g., voltage-dependent calcium (Cav) and sodium
(Nav) channel subunits, members of the transient receptor
potential (TRP) family, and glutamate receptors (complete list:
Supplementary Table 1). We have recently shown that mouse
spectral libraries can be applied for protein profiling across
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FIGURE 1 | Overview of our integrated workflow: from Sham-operated mice and the SNI model via mouse behavior, protein solubilization, quantitative DIA-MS and
data analysis to protein network dynamics. ACC, anterior cingulate cortex; AMY, amygdala; CER, cerebellum; DRG, dorsal root ganglia; PFC, prefrontal cortex; SC,
spinal cord; SN, sciatic nerve.
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species, i.e., also in humans (Bruderer et al., 2017b). Based on
its comprehensive protein coverage, our pan-mouse library can
be used for the standardized interrogation of diverse mouse and
human datasets in pain research. It contains information of 31%
of the genes represented in the Human Pain Genes Database
(HPGDB, https://humanpaingenetics.org/hpgdb/; Meloto et al.,
2017) as well as 45% of genes identified in pain-related transgenic
knockout studies summarized in the Pain Genes Database (PGD,
http://www.jbldesign.com/jmogil/enter.html; Lacroix-Fralish
et al., 2007; complete list: Supplementary Table 1). Therefore,
our pan-mouse library represents a valuable resource to profile
these pain-related proteins and others in human and rodent
tissues.
Next, we performed DIA-MS experiments according
to published procedures (Figure 1 workflow; Bruderer
et al., 2015, 2017a,b). This enabled us to quantify >5,000
proteins across DIA-MS runs. Applying very stringent
criteria for reproducibility of protein identification across
all replicates (please see Methods for details) resulted in highly
reproducible profiling of 3141-4103 proteins depending on the
tissue (Figures 2A–C; Supplementary Figure 2; complete
list: Supplementary Table 2). While the vast majority
of proteins were expressed across regions, differentially
expressed proteins could be determined when comparing
the brain proteome with SC and PNS proteomes (Figure 2C;
complete list: Supplementary Table 2). Among the latter, we
observed a significant overlap of SC and DRG proteomes
(Figure 2C), which is anatomically supported given that
spinal roots (central branches of DRG axons) innervate the
SC dorsal horn. Hierarchical clustering across individual
replicates further supports the similarity of the DRG and
SC proteomes (Figure 2A). Together, this data prompted
us to analyze the SC separately from other CNS (i.e., brain)
areas.
We then performed pathway analysis with IPA R© to determine
enriched canonical and disease pathways in each PNS, SC,
and brain region analyzed. IPA R© results recalled known global
and region-specific features, demonstrating the quality and
biological significance of identified proteomes (complete list:
Supplementary Table 3). Among the top pathways highly
enriched in the PNS compared to brain areas were acute
phase response signaling, LXR/RXR (liver x receptors/retinoid
x receptors) activation, the complement system, and the
superpathway of cholesterol biosynthesis. Proteins belonging
to these pathways are indicated in Supplementary Table 3.
Conversely, glutamate, GABA, and dopamine receptor signaling,
as well as synaptic long term potentiation/depression were found
to be enriched in analyzed brain tissues as expected. Moreover,
disease/functional pathways such as cognition, learning, seizures,
plasticity of synapse, locomotion, and schizophrenia were
highly represented in brain tissues compared to tissues of
the PNS (complete list: Supplementary Table 3). In contrast,
PNS and SC proteomes showed enrichment of proteins
involved in demyelinating neuropathy, fatty acid metabolism,
myopathy, and chronic skin disorder. Within the PNS we detected
differences attributable to the diverse biology of SN and DRG,
such as the overrepresentation of proteins associated with
(de)myelination, psoriasis, and chronic inflammatory disorder, as
well as extracellular matrix and adhesion in the SN vs. DRG.
Defining Discrete Protein Enrichment in
PNS and SC Proteomes
To objectively define PNS- and SC-enriched proteomes, we
performed a quantitative and subtractive cross-comparison with
the identified brain proteome, applying stringent selection
criteria (please seeMethods for details). First, protein enrichment
in the PNS or SC was defined by> 10-fold enrichment of protein
abundance. As a second filter, we used data published by Sharma
and colleagues (Sharma et al., 2015), which represents the most
extensive mouse brain proteome to date. We then again excluded
every protein from our PNS or SC-enriched protein compendium
that was not >10-fold enriched over any brain tissue using the
in silico library designed from data published by Sharma and
colleagues.
This procedure yielded the definition of 463 PNS-enriched
proteins, 164 of which were preferably expressed in DRG and
84 in SN (Figure 2D; complete list: Supplementary Table 4).
Among these proteins are several well-known key PNS proteins,
confirming the validity of our results. These include hallmark ion
channels of sensory neurons, such as the voltage-gated sodium
channels SCN11A and SCN10A, the TRP ion channel TRPV1
and its interaction partner PIRT, and the purinergic ion channel
P2RX3. Moreover, the SN proteome featured prominent myelin
proteins, e.g., proteolipidprotein 2 (PLP2), peripheral myelin
protein 2 (PMP2) andNCMAP, as well as several other candidates
with reported involvement in pain or PNS neurobiology:
thrombospondin-4 (TSP4), ciliary neurotrophic factor (CNTF),
Calcitonin gene-related peptide 1 (CGRP), follistatin 1 (FSTL1),
and the Schwann cell tight junction protein claudin 19 (CLDN19;
Miyamoto et al., 2005; Li et al., 2011a,b; Kim et al., 2012). The
latter four are shared among DRG and SN.
More interestingly, we detected many proteins which are
hardly characterized within the PNS. To illustrate, the tripartite
motif-containing 36 protein (TRIM36) is an E3 ubiquitin-protein
ligase which may bind microtubules and is involved in cell cycle
regulation (Miyajima et al., 2009). Interestingly, its transcript
has been found to be enriched in mouse and human DRG
(Ray et al., 2018). We further identified C-type lectin domain
family 10A (MMGL; Zizzari et al., 2015), which acts as an
immune system modulator, particularly during inflammation.
Members of the serpin family of serine protease inhibitors such
as SERPINA3N, SERPING1, and SERPINF1 were also found to
be enriched in the PNS. SERPINs are known to exhibit multiple
functions from controlling the complement system to acute
inflammatory immune responses (Gettins, 2002). SERPINF1
is notable as it lacks the protease inhibitory activity and is
known to be antiangiogenic and neurotrophic (Gettins et al.,
2002; Rychli et al., 2009). The role of SERPING1 and F1 in
the PNS is unknown, but worthwhile investigating: Vicuna and
colleagues have recently shown the prominent role of DRG-
derived SERPINA3N in promoting early phases of neuropathic
pain upon SNI (Vicuna et al., 2015).
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FIGURE 2 | Determination of PNS- and SC-enriched proteomes. (A) Unsupervised clustering of z-scored normalized protein intensities from all Sham replicates
(C1-C3; 4 mice each) across the 7 analyzed regions of the PNS and CNS. High experimental reproducibility becomes apparent. Furthermore, the clustering shows
expected similarities between related tissues, e.g., PNS tissues and spinal cord (SC) are more closely clustered together than the 4 brain regions. The different colors
of the y-axis dendrogram visualize exemplary clusters of proteins. (B) Number of proteins consistently detected across tissues. (C) Venn diagram illustrates
differentially expressed and shared proteins across SN, DRG, SC, and brain regions. (D) A quantitative comparative analysis reveals that 299 and 379 proteins are
enriched (> 10-fold) in SN and DRG proteomes (i.e., PNS-enriched) compared to the brain proteome. Further, tissue-specific expression of 84 (SN) and 164 (DRG)
proteins can be observed. The table lists examples of PNS-enriched proteins according to their expression in SN, DRG, or both.
Another prominent group, which is enriched in SN and has
some overlap with the DRG, are proteins associated with the
extracellular matrix (ECM). Among the enriched ECM proteins
in our PNS-resolved proteomes, we identified: Chondroitin
sulfate proteoglycan 4 (NG2; Fukushi et al., 2004), known to
contribute to cell migration, neurite outgrowth and angiogenesis;
latent transforming growth factor beta binding protein 4 (LTBP4;
Lamar et al., 2016), involved in muscular dystrophy through
the activity control of TGF-beta; dermatopontin (TRAMP;
Krishnaswamy et al., 2014), a stabilizer of collagen fibrils
facilitating wound healing; SPARC related modular calcium
binding 2 (SMOC2; Vannahme et al., 2003), implicated in
angiogenesis andmatrix assembly facilitating wound healing; and
extracellular matrix protein 1 (ECM1; Anderson et al., 2009)
with functions in tumor biology, skin integrity, and inflammatory
bowel disease.
We performed a similar analysis to define an SC-enriched
proteome (in comparison to the brain proteome) yielding
74 proteins (complete list: Supplementary Table 5). The SC-
enriched proteome contains the purinergic ion channel P2RX7
and other proteins known to be involved in nociception or
pain, including Fibroblast Growth Factor Receptor 1 (FGFR-
1) and S100 Calcium Binding Protein A8 (S100A8; Jamieson
et al., 2014). Like in our PNS-enriched list, proteins with largely
unexplored function in the SC can also be found. These include:
Tax1-binding protein 3 (TIP-1; Kanamori et al., 2003) with
effects on Wnt-signaling via catenin inhibition; microfibril-
associated glycoprotein 4 (MFAP4; Koyanagi et al., 2016),
an extracellular integrin ligand with glucocorticoid-dependent
diurnal oscillations in the SC; and zinc finger protein (DPF3;
Lange et al., 2008) implicated in developmental chromatin
remodeling.
Quality of Resolved PNS and SC
Proteomes
To determine the quality of our analysis, we assessed various
aspects of resolved PNS and SC proteomes. Considering the
importance of membrane proteins as drug targets (Dib-Hajj
et al., 2009; Patapoutian et al., 2009; Lunn, 2010; Raouf
et al., 2010; Antunes-Martins et al., 2013; Jamieson et al.,
2014), we performed a GO-based enrichment analysis for
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cellular compartment using the web interface DAVID (Huang
da et al., 2009). This revealed that membrane proteins
are well-represented in these proteomes: membrane proteins
constitute roughly 50% of proteins across analyzed proteomes,
approximately 40% of which are predicted to be localized to
the plasma membrane (PM) [SC: 50% (1897/3779) of which
40% (764/1897) at PM; DRG: 49.2% (2017/3817) of which
37.8% (764/2017) at PM; SN: 49.5% (1551/3136) of which 40.0%
(621/1551) at PM].
Next, we compared our datasets with published reports on
the molecular composition of the PNS and SC (complete list:
Supplementary Table 6). With few published proteome studies
on these tissues, we also included transcriptome data from
DRG, SN, and SC in our comparison. However, comparisons
between transcriptomes and proteomes often show major
discrepancies due to the well-known limited predictability of
mRNA alterations for protein levels (Schwanhausser et al.,
2011; Sharma et al., 2015; Liu et al., 2016). These limitations
need to be considered when interpreting data. Nonetheless,
our results demonstrate a significant overlap with previous -
omics studies on SC, SN, and DRG essentially validating our
datasets (Figure 3A). Our SN proteome comprises >70% of the
published rat SN membrane proteome (Lu et al., 2009) and
the mouse myelin proteome (Patzig et al., 2011). Moreover,
overlapping proteins represent 10% (31/299) and 35% (106/299)
of the SN-enriched proteome as defined above, respectively.
A comparison of our SC data with the published rat SC
membrane proteome (Lu et al., 2009) and the published
human SC proteome (Bruderer et al., 2017b) yielded similar
results, i.e., strong overlaps of >70% (Figure 3A; complete list:
Supplementary Table 6).
Remarkably, we also observed pronounced similarities
between the DRG proteome identified here and previous mRNA-
based studies on purified nociceptors (Thakur et al., 2014)
and sensory neuron subtypes of DRG (Usoskin et al., 2015;
Figure 3B). For example, 31% (1306/4103) of all identified
proteins in DRG and 33% (127/379) of DRG-enriched proteins
match nociceptor mRNA (Thakur et al., 2014), of which we
obtain a 47% (1306/2733) coverage on protein level (Figure 3B).
Even more, our DRG proteome list contains information on
29% (125/417 annotated mRNAs) of the characteristic top 50
members across most DRG subpopulations (Usoskin et al., 2015;
Figure 3B) including neurofilament-rich myelinated neurons
(NF), peptidergic nociceptors (PEP), nonpeptidergic nociceptors
(NP), and tyrosine hydroxylase-expressing neurons (TH; results
for neuronal subpopulations: Supplementary Figure 3 and
Supplementary Table 6). Given that we used lysates of whole
DRG containing glia and immune cells alongside neurons,
this analysis strongly suggests that a substantial part of our
dataset represents the neuronal proteome of DRG. The lists
of all comparisons and overlapping proteins can be found
in Supplementary Table 6. These findings validate our results
and support their significance for further hypothesis-driven
analysis at the protein level across cell types. They also highlight
their utility for discovering uncharacterized neuronal and non-
neuronal proteins.
Utility of Our Datasets for Translational
Pain Research
The motivation underlying high-throughput methodologies is
to identify novel molecular and mechanistic insights into
complex pathological processes. Therefore, we aimed at critically
examining whether our proteome datasets could also provide a
resource to explore the molecular set-up of painful pathologies
across species to enable translational work. First, we investigated
the coverage of genes and gene products reported to underlie
painful pathologies in humans and rodents. Again, we leveraged
previous data mining efforts and compared our data with the
Human Pain Gene Database [HPGDB, (Meloto et al., 2017)]
and with pain-related transgenic knockout studies summarized
in the Pain Genes Database [PGD, (Lacroix-Fralish et al., 2007)]
(complete list: Supplementary Table 7). Indeed, many pain-
related gene products are represented in our proteome datasets,
strongly supporting the utility of our data for investigating
pathological processes associated with pain: specifically, our PNS
proteome includes 17% of the HPGDB (23/129; 9 defined as
PNS-enriched) and 30% of the PGD (133/435; 31 defined as
PNS-enriched ones). Similar values were obtained for the SC
proteome, with 16% of the HPGDB (21/129; 2 defined as SC-
enriched) and 26% of the PGD (116/435; 2 defined as SC-
enriched).
Considering that side effects on key bodily functions limit
current therapeutic options of many painful disorders, defining
a PNS-enriched set of proteins in a body-wide manner is
of immense importance (Patapoutian et al., 2009; Borsook
et al., 2014; Berta et al., 2017b; Ray et al., 2018). Excellent
recent studies have systematically investigated this on the
transcriptome level by comparing human and mouse datasets
(Sapio et al., 2016; Ray et al., 2018). They reported a PNS-
enriched and DRG-enriched transcriptome, respectively, which
is conserved between mouse and humans. Intriguingly, we
observed a significant overlap with our PNS-enriched datasets
(complete list: Supplementary Table 7): Our full PNS proteome
comprises 75% (27/36) of reported human PNS-enriched gene
products (Sapio et al., 2016) including 19% (7/36) in our list
of PNS-enriched proteins, such as PNS hallmark ion channels
SCN11A, SCN10A, and TRPV1 (Figure 3C). Moreover, among
the 84 conserved and DRG-enriched transcripts described by
Ray and colleagues (Ray et al., 2018), we detected 35% (30/84)
at the protein level in DRG. Of these 30 proteins, 17 match
to our DRG-enriched dataset and 20 to our PNS-enriched
dataset including aforementioned hallmark proteins of the PNS
(Figure 3C; complete list: Supplementary Table 7).
Despite these matches, we recognize that our proteome
data (i) lacks information on 65% (54/84 reported by Ray
and colleagues; Ray et al., 2018) of conserved and DRG-
enriched transcripts, and (ii) on the other hand, does not
confirm the DRG-enrichment of others at the protein level.
To illustrate the latter, we identified 13 proteins in our
brain proteome (Supplementary Table 2), including stathmin
2 (STMN2), tubulin-beta 3 (TUBB3), collagen 28 (COL28A1),
protein prune homolog 2 (PRUNE2), and known DRG marker
proteins like advillin (AVIL) and peripherin (PRPH; complete
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FIGURE 3 | Comparison of PNS and SC proteomes with previously published reports in mice and humans. (A) Comparison of our SN or SC proteomes with
published proteome studies: SN mouse myelin proteome (Patzig et al., 2011), SN rat membrane proteome (Lu et al., 2009), SC rat membrane proteome (Lu et al.,
2009), and SC human proteome (Bruderer et al., 2017b). (B) Comparison of our DRG proteomes with published DRG transcriptome/RNA-seq studies: mouse DRG
nociceptors (Thakur et al., 2014) and mouse DRG neuronal subpopulations (Usoskin et al., 2015). (C) Comparison of our PNS and DRG proteomes with studies on
the human PNS-enriched transcriptome (Sapio et al., 2016) and the human DRG-enriched transcriptome (Ray et al., 2018).
list: Supplementary Table 7). Reasons for the missing proteins
in our data are likely related to well-known limitations of
proteomics approaches in detecting low abundant proteins in
complex samples; notably for transmembrane proteins. On
the other hand, many studies have demonstrated a prominent
mismatch between transcriptome and proteome data due to
posttranslational modifications, altered protein stability, and
cellular buffering mechanisms (Schwanhausser et al., 2011;
Sharma et al., 2015; Liu et al., 2016). Hence, mismatches in
defining protein-enrichment may arise.
To address this, in part, we extended our definition of PNS-
enriched proteins with respect to their body-wide expression
pattern in humans at the protein level. To this end, we employed
the exhaustive immunohistochemistry-based dataset available in
the Human Protein Atlas (Uhlen et al., 2015; Thul et al., 2017),
which contains protein expression data on 30 different tissues,
but excludes the PNS and SC. We scrutinized our mouse PNS-
enriched proteome data for those proteins that did not match
the Human Protein Atlas. Notably, we uncovered 31% (142/463)
as putative PNS-enriched candidate proteins in humans given
the previously shown good agreement between sensory neurons
in mice and humans (Sapio et al., 2016; Lopes et al., 2017;
Ray et al., 2018). Validating our results, this list contains well
known PNS proteins (TRPV1, PIRT, SCN11A, SCN10A, P2RX3,
CLDN19, CNTF) as well as diverse myelin proteins of the SN,
like noncompact myelin-associated protein (MP11), myelin P2
protein (MYP2), and myelin protein P0 (MYP0; complete list:
Table 1). The list also encompasses 14 candidates reported by
Ray and colleagues (Ray et al., 2018) to be DRG-enriched and
conserved in humans (labeled with ∗ in Table 1).
More importantly, our analysis highlighted many likely
human PNS-enriched proteins whose functional relevance in
the PNS is not well understood. Diverse collagens (COBA1,
COEA1, CO1A1, CO3A1), along with their receptors (integrin
alpha-1) and their binding proteins (fibromodulin) appear
to be enriched in the PNS. Together with dermatopontin
and lumican they are involved in GO_BP pathways of
extracellular matrix and collagen fibril organization, respectively
(enrichment FDR: 0.00038 and 0.00258). We also observed
a significant enrichment of proteins implicated in GO_BP
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TABLE 1 | List of putative PNS-enriched candidate proteins in humans.
Entry Protein names Gene names
Q9WV68 Peroxisomal 2,4-dienoyl-CoA reductase (EC 1.3.1.34) (2,4-dienoyl-CoA reductase 2) Decr2 Pdcr
Q9WUP4 Polyprenol reductase (EC 1.3.1.94) (3-oxo-5-alpha-steroid 4-dehydrogenase 3) (EC 1.3.1.22) (Steroid
5-alpha-reductase 2-like) (Steroid 5-alpha-reductase 3) (S5AR 3) (SR type 3)
Srd5a3
Srd5a2l
Q9WU66* Secreted frizzled-related protein 5 (sFRP-5) Sfrp5
Q9R059 Four and a half LIM domains protein 3 (FHL-3) (Skeletal muscle LIM-protein 2) (SLIM-2) Fhl3
Q9R053* Sodium channel protein type 11 subunit alpha (NaN) (Sensory neuron sodium channel 2) (Sodium channel protein type
XI subunit alpha) (Voltage-gated sodium channel subunit alpha Nav1.9)
Scn11a Nan
Nat Sns2
Q9QZZ6 Dermatopontin (Early quiescence protein 1) (EQ-1) (Tyrosine-rich acidic matrix protein) (TRAMP) Dpt
Q9QYY0 GRB2-associated-binding protein 1 (GRB2-associated binder 1) (Growth factor receptor bound protein 2-associated
protein 1)
Gab1
Q9JLK7 Calcium-binding protein 1 (CaBP1) Cabp1
Q9JLB2 MAGUK p55 subfamily member 5 (Protein associated with Lin-7 1) Mpp5 Pals1
Q9JKJ9 24-hydroxycholesterol 7-alpha-hydroxylase (EC 1.14.14.26) (Cytochrome P450 39A1) (mCYP39A1) (Oxysterol
7-alpha-hydroxylase)
Cyp39a1
Q9JJH1 Ribonuclease 4 (RNase 4) (EC 3.1.27.-) Rnase4
Q9ET38* Claudin-19 (CLDN19) Cldn19
Q9ESB3 Histidine-rich glycoprotein (Histidine-proline-rich glycoprotein) (HPRG) Hrg
Q9ERA0 Alpha-globin transcription factor CP2 Tfcp2 Tcfcp2
Q9ER60 Sodium channel protein type 4 subunit alpha (Sodium channel protein skeletal muscle subunit alpha) (Sodium channel
protein type IV subunit alpha) (Voltage-gated sodium channel subunit alpha Nav1.4)
Scn4a
Q9EPX2 Papilin Papln
Q9EPV8 Ubiquitin-like protein 5 Ubl5
Q9EPL9 Peroxisomal acyl-coenzyme A oxidase 3 (EC 1.3.3.6) (Branched-chain acyl-CoA oxidase) (BRCACox) (Pristanoyl-CoA
oxidase)
Acox3
Q9EPB5 Serine hydrolase-like protein (SHL) (EC 3.1.-.-) Serhl
Q9DBN5 Lon protease homolog 2, peroxisomal (EC 3.4.21.-) (Lon protease-like protein 2) (Lon protease 2) (Peroxisomal Lon
protease)
Lonp2
Q9DBG7 Signal recognition particle receptor subunit alpha (SR-alpha) (Docking protein alpha) (DP-alpha) Srpra Srpr
Q9DBD0 Inhibitor of carbonic anhydrase Ica
Q9DB16 Calcium-binding protein 39-like (MO25beta) (Mo25-like protein) Cab39l
Q9D2R4 Transmembrane emp24 domain-containing protein 11 (Glycoprotein 25L) (GP25L) (p24 family protein alpha-1)
(p24alpha1)
Tmed11
Q9D281 Protein Noxp20 (Nervous system overexpressed protein 20) (Protein FAM114A1) Fam114a1
Noxp20
Q9CXX9 CUE domain-containing protein 2 Cuedc2
Q9CWP6 Motile sperm domain-containing protein 2 Mospd2
Q9CWG8 Protein arginine methyltransferase NDUFAF7, mitochondrial (EC 2.1.1.320) (NADH dehydrogenase [ubiquinone]
complex I, assembly factor 7) (Protein midA homolog)
Ndufaf7
Q9CQW9 Interferon-induced transmembrane protein 3 (Dispanin subfamily A member 2b) (DSPA2b) (Fragilis protein)
(Interferon-inducible protein 15) (Mouse ifitm-like protein 1) (Mil-1)
Ifitm3
Q9CQ20 Mid1-interacting protein 1 (Gastrulation-specific G12-like protein) (Mid1-interacting G12-like protein) (Protein
STRAIT11499 homolog) (Spot 14-related protein) (S14R) (Spot 14-R)
Mid1ip1 Mig12
Q99PM3 Transcription initiation factor IIA subunit 1 (General transcription factor IIA subunit 1) [Cleaved into: Transcription
initiation factor IIA alpha chain (TFIIA p35 subunit); Transcription initiation factor IIA beta chain (TFIIA p19 subunit)]
Gtf2a1
Q99M08 Uncharacterized protein C4orf3 homolog NA
Q99LJ6 Glutathione peroxidase 7 (GPx-7) (GSHPx-7) (EC 1.11.1.9) Gpx7
Q99JS0* Noncompact myelin-associated protein (Myelin protein of 11 kDa) (MP11) Ncmap
Q99JF5 Diphosphomevalonate decarboxylase (EC 4.1.1.33) (Mevalonate (diphospho)decarboxylase) (MDDase) (Mevalonate
pyrophosphate decarboxylase)
Mvd
Q99JA0* Calcitonin gene-related peptide 1 (Alpha-type CGRP) (Calcitonin gene-related peptide I) (CGRP-I) Calca Calc
Q923B6 Metalloreductase STEAP4 (EC 1.16.1.-) (Dudulin-4) (Six-transmembrane epithelial antigen of prostate 4) (Tumor
necrosis factor-alpha-induced adipose-related protein)
Steap4 Tiarp
(Continued)
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Q921L5 Conserved oligomeric Golgi complex subunit 2 (COG complex subunit 2) (Component of oligomeric Golgi complex 2)
(Low density lipoprotein receptor defect C-complementing protein)
Cog2 Ldlc
Q91YI4 Beta-arrestin-2 (Arrestin beta-2) Arrb2
Q91WP6 Serine protease inhibitor A3N (Serpin A3N) Serpina3n Spi2
Q91W59 RNA-binding motif, single-stranded-interacting protein 1 (Single-stranded DNA-binding protein MSSP-1) Rbms1 Mssp Mssp1




Q8VE11 Myotubularin-related protein 6 (EC 3.1.3.-) Mtmr6
Q8VC98* Pleckstrin homology domain-containing family A member 4 (PH domain-containing family A member 4)
(Phosphoinositol 3-phosphate-binding protein 1) (PEPP-1)
Plekha4 Pepp1
Q8R3U1 HRAS-like suppressor 3 (HRSL3) (EC 3.1.1.32) (EC 3.1.1.4) (Adipose-specific phospholipase A2) (AdPLA) (Group XVI
phospholipase A2) (H-rev 107 protein homolog)
Pla2g16 H-rev107
Hrasls3 Hrev107
Q8R3I3 Conserved oligomeric Golgi complex subunit 6 (COG complex subunit 6) (Component of oligomeric Golgi complex 6) Cog6 Kiaa1134
Q8R3I2 Lysophospholipid acyltransferase 2 (LPLAT 2) (EC 2.3.1.-) (1-acylglycerophosphocholine O-acyltransferase) (EC
2.3.1.23)
Mboat2 Lpcat4 Oact2
Q8R189 Monocyte to macrophage differentiation factor 2 (Progestin and adipoQ receptor family member X) Mmd2 Paqr10
Q8R100 Protein FAM26E Fam26e
Q8K4K6 Pantothenate kinase 1 (mPank) (mPank1) (EC 2.7.1.33) (Pantothenic acid kinase 1) Pank1 Pank
Q8K2V1 Serine/threonine-protein phosphatase 4 regulatory subunit 1 Ppp4r1
Q8K296 Myotubularin-related protein 3 (EC 3.1.3.48) (Phosphatidylinositol-3,5-bisphosphate 3-phosphatase) (EC 3.1.3.95)
(Phosphatidylinositol-3-phosphate phosphatase) (EC 3.1.3.64)
Mtmr3
Q8K1B8 Fermitin family homolog 3 (Kindlin-3) (Unc-112-related protein 2) Fermt3 Kind3 Urp2
Q8CI59 Metalloreductase STEAP3 (EC 1.16.1.-) (Dudulin-2) (Protein nm1054) (Six-transmembrane epithelial antigen of prostate
3) (Tumor suppressor-activated pathway protein 6)
Steap3 Tsap6
Q8CG14 Complement C1s-A subcomponent (EC 3.4.21.42) (C1 esterase) (Complement component 1 subcomponent s-A)
[Cleaved into: Complement C1s-A subcomponent heavy chain; Complement C1s-A subcomponent light chain]
C1sa C1s
Q8CD91 SPARC-related modular calcium-binding protein 2 (Secreted modular calcium-binding protein 2) (SMOC-2) Smoc2
Q8C650 Septin-10 Sept10
Q8C008 Double zinc ribbon and ankyrin repeat-containing protein 1 Dzank1
Q8BWL5 RNA-binding motif, single-stranded-interacting protein 3 Rbms3
Q8BS95 Golgi pH regulator (Protein GPR89) Gpr89a Gphr Gpr89
Q8BRH3 Rho GTPase-activating protein 19 (Rho-type GTPase-activating protein 19) Arhgap19
Q8BND5 Sulfhydryl oxidase 1 (mSOx) (EC 1.8.3.2) (Quiescin Q6) (Skin sulfhydryl oxidase) Qsox1 Qscn6 Sox
Q8BMB3 Eukaryotic translation initiation factor 4E type 2 (eIF-4E type 2) (eIF4E type 2) (eIF4E-2) (mRNA cap-binding protein type
2) (Eukaryotic translation initiation factor 4E-like 3) (eIF4E-like protein 4E-LP)
Eif4e2 Eif4el3
Q8BH97 Reticulocalbin-3 Rcn3 D7Ertd671e
Q8BGD6 Sodium-coupled neutral amino acid transporter 9 (Solute carrier family 38 member 9) Slc38a9
Q8BFY0* Phosphoinositide-interacting protein Pirt
Q80X19 Collagen alpha-1(XIV) chain (COEA1) Col14a1
Q80WG7* E3 ubiquitin-protein ligase Trim36 (EC 2.3.2.27) (Acrosome RBCC protein) (Haprin) (RING-type E3 ubiquitin transferase
TRIM36) (Tripartite motif-containing protein 36)
Trim36
Q80VM7 Ankyrin repeat domain-containing protein 24 Ankrd24
Q7TQ62 Podocan Podn
Q704Y3* Transient receptor potential cation channel subfamily V member 1 (TrpV1) (Osm-9-like TRP channel 1) (OTRPC1)
(Vanilloid receptor 1)
Trpv1
Q6QIY3* Sodium channel protein type 10 subunit alpha (Peripheral nerve sodium channel 3) (PN3) (Sensory neuron sodium
channel) (Sodium channel protein type X subunit alpha) (Voltage-gated sodium channel subunit alpha Nav1.8)
Scn10a Sns
Q6PFX8 N-acetylaspartylglutamate synthase A (NAAG synthetase A) (NAAGS) (EC 6.3.2.41) (N-acetylaspartylglutamylglutamate
synthase A) (EC 6.3.2.42) (Ribosomal protein S6 modification-like protein A)
Rimkla Fam80a Rimk
Q6NZK8 Protein tyrosine phosphatase domain-containing protein 1 (EC 3.1.3.-) Ptpdc1
Q6A009 E3 ubiquitin-protein ligase listerin (EC 2.3.2.27) (RING finger protein 160) (RING-type E3 ubiquitin transferase listerin)
(Zinc finger protein 294) (Zfp-294)
Ltn1 Kiaa0714 Lister
Rnf160 Zfp294 Znf294
Q62147 Sarcospan (K-ras oncogene-associated protein) (Kirsten-Ras-associated protein) Sspn Krag
(Continued)
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Q61245 Collagen alpha-1(XI) chain (COBA1) Col11a1
Q60632 COUP transcription factor 1 (COUP-TF1) (COUP transcription factor I) (COUP-TF I) (Nuclear receptor subfamily 2 group
F member 1) (V-erbA-related protein 3) (EAR-3)
Nr2f1 Erbal3 Tfcoup1
Q5FW60 Major urinary protein 20 (Darcin) (Major urinary protein 24) Mup20 Mup24
Q3V4B5 COMM domain-containing protein 6 Commd6
Q3V3R4 Integrin alpha-1 (CD49 antigen-like family member A) (Laminin and collagen receptor) (VLA-1) (CD antigen CD49a) Itga1
Q3UZV7 UPF0577 protein KIAA1324-like homolog (Estrogen-induced gene 121-like protein) (EIG121L) NA
Q3UR32* P2X purinoceptor 3 (P2X3) (ATP receptor) (Purinergic receptor) P2rx3
Q3UPR9 Somatomedin-B and thrombospondin type-1 domain-containing protein (RPE-spondin) Sbspon Gm106 Rpesp
Q3TZX8 Polynucleotide 5′-hydroxyl-kinase NOL9 (EC 2.7.1.-) (Nucleolar protein 9) Nol9
Q01339 Beta-2-glycoprotein 1 (APC inhibitor) (Activated protein C-binding protein) (Apolipoprotein H) (Apo-H)
(Beta-2-glycoprotein I) (B2GPI) (Beta(2)GPI)
Apoh B2gp1
P82347 Delta-sarcoglycan (Delta-SG) (35 kDa dystrophin-associated glycoprotein) (35DAG) Sgcd
P70271 PDZ and LIM domain protein 4 (LIM protein RIL) (Reversion-induced LIM protein) Pdlim4 Ril
P70160* Calcitonin Calca Calc
P70158 Acid sphingomyelinase-like phosphodiesterase 3a (ASM-like phosphodiesterase 3a) (EC 3.1.4.-) Smpdl3a Asml3a
P57724 Poly(rC)-binding protein 4 (Alpha-CP4) Pcbp4
P51885 Lumican (Keratan sulfate proteoglycan lumican) (KSPG lumican) Lum Lcn Ldc
P51642* Ciliary neurotrophic factor (CNTF) Cntf
P50608 Fibromodulin (FM) (Collagen-binding 59 kDa protein) (Keratan sulfate proteoglycan fibromodulin) (KSPG fibromodulin) Fmod
P50285 Dimethylaniline monooxygenase [N-oxide-forming] 1 (EC 1.14.13.8) (Dimethylaniline oxidase 1) (Hepatic
flavin-containing monooxygenase 1) (FMO 1)
Fmo1 Fmo-1
P48410 ATP-binding cassette sub-family D member 1 (Adrenoleukodystrophy protein) (ALDP) Abcd1 Ald Aldgh
P47880 Insulin-like growth factor-binding protein 6 (IBP-6) (IGF-binding protein 6) (IGFBP-6) Igfbp6 Igfbp-6
P46412 Glutathione peroxidase 3 (GPx-3) (GSHPx-3) (EC 1.11.1.9) (Plasma glutathione peroxidase) (GPx-P) (GSHPx-P) Gpx3
P43135 COUP transcription factor 2 (COUP-TF2) (Apolipoprotein AI regulatory protein 1) (ARP-1) (COUP transcription factor II)
(COUP-TF II) (Nuclear receptor subfamily 2 group F member 2)
Nr2f2 Aporp1 Arp-1
Arp1 Tfcoup2
P42925 Peroxisomal membrane protein 2 (22 kDa peroxisomal membrane protein) Pxmp2 Pmp22
P40936 Indolethylamine N-methyltransferase (Indolamine N-methyltransferase) (EC 2.1.1.49) (EC 2.1.1.96) (Aromatic
alkylamine N-methyltransferase) (Amine N-methyltransferase) (Arylamine N-methyltransferase) (Thioether
S-methyltransferase) (TEMT)
Inmt Temt
P33622 Apolipoprotein C-III (Apo-CIII) (ApoC-III) (Apolipoprotein C3) Apoc3
P24526 Myelin P2 protein (MYP2) Pmp2
P21812 Mast cell protease 4 (mMCP-4) (EC 3.4.21.-) (MSMCP) (Myonase) (Serosal mast cell protease) Mcpt4
P19258 Protein Mpv17 (Mpv-17) Mpv17
P14483 H-2 class II histocompatibility antigen, A beta chain H2-Ab1 H2-iabeta
P11589 Major urinary protein 2 (MUP 2) Mup2
P08121 Collagen alpha-1(III) chain (CO3A1) Col3a1
P08074 Carbonyl reductase [NADPH] 2 (EC 1.1.1.184) (Adipocyte protein P27) (AP27) (Lung carbonyl reductase) (LCR)
(NADPH-dependent carbonyl reductase 2)
Cbr2
P06909 Complement factor H (Protein beta-1-H) Cfh Hf1
P06684 Complement C5 (Hemolytic complement) [Cleaved into: Complement C5 beta chain; Complement C5 alpha chain;
C5a anaphylatoxin; Complement C5 alpha’ chain]
C5 Hc
P06330 Ig heavy chain V region AC38 205.12 NA
P04938 Major urinary protein 11 Mup11 Mup9
P03987 Ig gamma-3 chain C region NA
P03975 IgE-binding protein Iap
P03953 Complement factor D (EC 3.4.21.46) (28 kDa adipocyte protein) (Adipsin) (C3 convertase activator) (Properdin factor D) Cfd Adn Df
P02762 Major urinary protein 6 (MUP 6) (Alpha-2U-globulin) (Group 1, BS6) (allergen Mus m 1) Mup6
P01872 Ig mu chain C region Ighm Igh-6
P01869 Ig gamma-1 chain C region, membrane-bound form Ighg1 Igh-4
P01868 Ig gamma-1 chain C region secreted form Ighg1 Igh-4
(Continued)
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P01864 Ig gamma-2A chain C region secreted form (B allele) NA
P01843 Ig lambda-1 chain C region NA
P01837 Ig kappa chain C region Igkc
O89013 Leptin receptor gene-related protein (Endospanin-1) (OB-R gene-related protein) (OB-RGRP) Leprot Lepr Obr
O88630 Golgi SNAP receptor complex member 1 (28 kDa Golgi SNARE protein) (28 kDa cis-Golgi SNARE p28) (GOS-28) Gosr1 Gs28
O88327 Alpha-catulin (Alpha-catenin-related protein) (ACRP) (Catenin alpha-like protein 1) Ctnnal1 Catnal1
O70258 Epsilon-sarcoglycan (Epsilon-SG) Sgce
O35744 Chitinase-like protein 3 (EC 3.2.1.52) (Beta-N-acetylhexosaminidase Ym1) (Chitinase-3-like protein 3) (ECF-L)
(Eosinophil chemotactic cytokine) (Secreted protein Ym1)
Chil3 Chi3l3 Ym1
B1AVZ0 Uracil phosphoribosyltransferase homolog Uprt
B1AS29 Glutamate receptor ionotropic, kainate 3 (GluK3) (Glutamate receptor 7) (GluR-7) (GluR7) Grik3 Glur7
A2BIM8 Major urinary protein 18 Mup18 Mup16
Q9JK53 Prolargin (Proline-arginine-rich end leucine-rich repeat protein) Prelp
Q9D4V3 Coiled-coil domain-containing protein 83 Ccdc83
Q91XI1 tRNA-dihydrouridine(47) synthase [NAD(P)(+)]-like (EC 1.3.1.-) (tRNA-dihydrouridine synthase 3-like) Dus3l
P60060 Protein transport protein Sec61 subunit gamma Sec61g
P27573* Myelin protein P0 (MYP0) (Myelin peripheral protein) (MPP) (Myelin protein zero) Mpz P0
P21183 Interleukin-5 receptor subunit alpha (IL-5 receptor subunit alpha) (IL-5R subunit alpha) (IL-5R-alpha) (IL-5RA) (CD
antigen CD125)
Il5ra Il5r
Q8R502 Volume-regulated anion channel subunit LRRC8C (Factor for adipocyte differentiation 158) (Leucine-rich
repeat-containing protein 8C)
Lrrc8c Ad158 Fad158
P11087 Collagen alpha-1(I) chain (Alpha-1 type I collagen) (CO1A1) Col1a1 Cola1
P10493 Nidogen-1 (NID-1) (Entactin) Nid1 Ent
P07758 Alpha-1-antitrypsin 1-1 (AAT) (Alpha-1 protease inhibitor 1) (Alpha-1-antiproteinase) (Serine protease inhibitor 1-1)
(Serine protease inhibitor A1a) (Serpin A1a)
Serpina1a Dom1
Spi1-1
Q3TGW2 Endonuclease/exonuclease/phosphatase family domain-containing protein 1 Eepd1 Kiaa1706
Comparison of our PNS-enriched proteome with the content of the Human Protein Atlas (Uhlen et al., 2015; Thul et al., 2017). Non-matching proteins are listed. Given the previously
shown good agreement between sensory neurons in mice and humans, these listed proteins are putatively enriched in the human PNS. Moreover, proteins reported by Ray and
colleagues (Ray et al., 2018) to be DRG-enriched and conserved in humans are labeled with *.
pathway of lipid metabolic processes (enrichment FDR: 0.037).
These include diverse enzymes (e.g., branched-chain acyl-
CoA oxidase, lysophospholipid acyltransferases 2 and 5, acid
sphingomyelinase-like phosphodiesterase 3a and members of
the myotubularin-related protein family). They catalyze lipid
mediators with known roles in signaling cascades relevant for
chronic pain such as sphingolipids (Patti et al., 2012) and
lysophosphatidylcholine (LPC; Inoue et al., 2008), encouraging
functional studies on these enzymes. Interestingly, our analysis
also suggests several major urinary proteins (MUPs) to be
enriched in the PNS. MUPs are known to bind lipophilic
pheromones and are excreted in urine to mediate social
communication in rodents (Hurst et al., 2001). However, their
additional (patho) physiological functions are unclear and may
be related to GO-BP lipid storage (enrichment FDR: 0.00731)
and glucose metabolism (enrichment FDR: 0.037; Hui et al., 2009;
Zhou et al., 2009). Moreover, the relationship betweenMUPs and
neuropathic pain still needs to be determined.
Taken together, our PNS-enriched proteome will serve as a
valuable resource for translational studies: This is encouraged
by the high similarity between the mouse and human PNS
(Sapio et al., 2016; Lopes et al., 2017; Ray et al., 2018)
as well as our recent demonstration that mouse spectral
libraries can be applied for protein profiling of human tissues
(Bruderer et al., 2017b). Future work will require validated
antibodies to reliably determine the localization of here identified
PNS-enriched proteins in mouse and human. In particular,
proteins which have not been characterized in the PNS
before may represent novel players in peripheral pathologies,
including pain, and should be queried for their functional
role.
Validation of Region Resolved Proteomes
in the SNI Model of Neuropathic Pain
Thus far, we have demonstrated that PNS and SC proteomes
can be comprehensively defined, and can also be employed
to interrogate - at the protein level - the molecular set-up of
tissues and pathologies across species. Next, we applied our DIA-
MS analysis workflow to an ongoing endeavor in the field of
chronic pain: The definition of a protein signature of chronic pain
(Costigan, 2012). Knowledge of such a protein signature can be
exploited for mechanism-oriented research and, ultimately, may
offer opportunities for novel therapeutic approaches (Gereau
et al., 2014; Baron et al., 2017). To this end we employed
the widely-used SNI model, which mimics clinically relevant
features including hypersensitivity to mechanical stimuli (tactile
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allodynia; Decosterd and Woolf, 2000). All SNI mice included in
this study exhibited pronounced hypersensitivity to mechanical
stimulation at 4 weeks, in contrast to Sham operated mice
(Supplementary Figure 1).
We quantitatively compared our PNS and SC datasets
obtained by DIA-MS from control (Sham surgery) mice with
those which underwent SNI. We again had highest demands
toward reproducibility and applied very stringent analysis
criteria: proteins were only included in our analysis if their
peptides were consistently detected in all six replicates, i.e., in
three Sham and in three SNI replicates for a given tissue (4
mice/replicate, totaling 12 mice/condition; please see Methods
for details). The heatmap of protein abundance across tissues and
correlation analyses can be found in Supplementary Figure 4.
Overall, more than 93% of proteins detected in control tissues
were consistently quantified in all six replicates (complete
list: Supplementary Table 8). These include 400 PNS-enriched
proteins and 41 SC-enriched proteins. At this point it is
unclear why the detection of SC-enriched proteins across all
six replicates yielded only 55% (41/74) of proteins identified
in control replicates described above (Supplementary Table 8).
This contrasts with the high reproducibility of DIA-MS in PNS
tissues and might hint at a massive downregulation of SC-
enriched proteins below the detection limit in SNI samples.
Upon statistical comparison of these data (please see Methods
for details), we observed distinct and tissue-specific changes
after SNI (Figures 4A–C; complete list: Supplementary Table 8).
Most regulated proteins were in the SN (1026/2939, 34%)
followed by DRG (715/3828, 18%) and SC (53/3584, 1.4%;
Figures 4A–C). For the latter, more than half of the proteins
were shared with the PNS as expected from aforementioned data
(Figure 4D). Strikingly, 29% (114/400; 58 in DRG and 88 in SN;
overlap in 32 proteins) of our PNS-enriched proteome showed
significant alterations during neuropathic pain (Figure 4E).
Among these, were 32 proteins that do not match the content of
the Human Protein Atlas (Uhlen et al., 2015; Thul et al., 2017),
thus, candidates considered to be putatively enriched in the
human PNS (Table 2). These include several proteins involved in
ECM integrity (e.g., some collagens, fibromodulin, and lumican).
Supporting our findings, a comparison with the catalog
of protein-protein interactions involved in neuropathic pain
(Jamieson et al., 2014), the PGD (Lacroix-Fralish et al., 2007),
and the HPGDB (Meloto et al., 2017) revealed links of many
SNI-regulated proteins to painful conditions in mouse and
human. These include well-known pain-related gene products
like nerve growth factor receptor (NGFR), annexin A2 (ANXA2),
alpha2/delta subunit 1 of the voltage-dependent calcium channel
(CACNA2d1), calcitonin gene-related peptide 1 (CGRP1 or
CALCA), thrombospondin 4 (THBS4), and follistatin-like 1
(FSTL1; complete list: Supplementary Table 9).
More importantly, we found largely uncharacterized
regulations. Several members of the aforementioned serpin
family of serine protease inhibitors are upregulated in SN
(e.g., SERPINA1C SERPINB6, SERPINC1, SERPINF1) or in
DRG and SN (e.g., SERPINB1A, SERPING1, SERPINH1).
GO-BP classification implicate these regulated SERPINs in acute
inflammatory responses, in processes related to wound healing
and, in general, related to the regulation of stress responses.
Periostin (PSTN) is also prominently upregulated in SN and
DRG in addition to being enriched in the PNS. There, it is
likely secreted from dermal fibroblasts (Murota et al., 2017). It
plays a role in cell adhesion and ECM integrity with a strong
impact on inflammatory pathologies of the skin (e.g., atopic
dermatitis) as well as the bowels (Koh et al., 2016; Murota et al.,
2017).
Moreover, we have identified prominent protein
downregulations after SNI. Dystrophin-related protein 2 (DRP-
2) is among PNS-enriched proteins which are downregulated in
SN. It is crucial for myelination in Schwann cells (Sherman et al.,
2001) and, thus, has been linked to demyelinating neuropathies
in both mouse and human (Sherman et al., 2001; Brennan et al.,
2015). In the SC, a top-downregulated candidate is the low
molecular weight protein thymosin beta4 (TYB4). Given its anti-
inflammatory and angiogenic functions, TYB4 has consistently
been shown to facilitate the repair and regeneration of diverse
tissues and diabetic neuropathy mice (Philp and Kleinman, 2010;
Wang et al., 2012). Hence, further exploration of TYB4 in the
context of chronic pain may uncover an analgesic potential.
Similarities and Differences Between
Inflammatory and Neuropathic Pain
Uncovered by Retrospective Analysis
Our results suggest a prominent regulation of candidate proteins
with roles in inflammatory and immune processes upon
SNI. This supports the notion that the immune system and
inflammation are critical players underlying SNI pathologies
(Krames, 2014; Ji et al., 2016; Sommer, 2016; Price and Gold,
2017; Cobos et al., 2018). Thus, we exploited the benefits of
DIA-MS to retrospectively extend the analysis of our previously
published datasets on chronic pain, specifically on the regulation
of the DRG membrane proteome during inflammatory (upon
injection of CFA) and neuropathic pain (SNI-model; Rouwette
et al., 2016). As explained above (Figure 1) DIA-MS data are
analyzed by means of spectral libraries. Hence, the depth and
quality of the spectral library largely determine the proteome
coverage one can obtain by a given experiment. The pan-
mouse library generated here contains approximately 2-fold
more proteins than our previously published spectral library
(Rouwette et al., 2016). We employed this superior pan-mouse
library to retrospectively extend our insights on pain-induced
changes within the DRG membrane proteome.
Compared to our previous study (Rouwette et al., 2016),
we identified dozens of additional proteins which appear to be
regulated in only one of the two chronic pain models (CFA:
235, previously: 64; SNI: 156, previously 77). To give some
examples, microsomal glutathione S-transferase 3 (MGST3)
is downregulated during inflammatory pain. This protein
belongs to a large family of peroxidase proteins involved in
the production of leukotrienes and prostaglandin E (Bresell
et al., 2005; Hayes et al., 2005). Notably, Hirai et al. (Hirai
et al., 2017) have identified MGST3 through RNA sequencing
after sciatic nerve entrapment (SNE) injury in rats, although
it’s role has not yet been examined in detail. Another example
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FIGURE 4 | Proteome dynamics in the SNI model of neuropathic pain. (A–C) Volcano plots show the regulation of members of SN, DRG, and SC proteomes in Sham
mice versus SNI mice. –log10 q-value is plotted against log2 fold change (SNI/Sham). The dotted horizontal line represents the cutoff for significance, q < 0.05. Tables
list examples of regulated candidates in each region and respective log2 fold changes (complete list: Supplementary Table 8). (D) Venn diagram illustrates regulated
(q < 0.05) proteins across SN, DRG, and SC proteomes. (E) Venn diagram illustrates regulated (q < 0.05) and differentially expressed proteins of the PNS-enriched
proteome. In all panels the q-value represents the Benjamini-Hochberg-corrected p-value.
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TABLE 2 | List of putative PNS-enriched candidate proteins in humans that are regulated upon SNI.
Entry Protein names Gene names Log2 (Pain/Sham) q-value
DRG SN DRG SN
Q80X19 Collagen alpha-1(XIV) chain Col14a1 0.28 0.11 0.000 0.001
P10493 Nidogen-1 (NID-1) (Entactin) Nid1 Ent 0.17 0.08 0.000 0.049
Q9JK53 Prolargin (Proline-arginine-rich end leucine-rich repeat protein) Prelp 0.39 −0.20 0.000 0.000
P51885 Lumican (Keratan sulfate proteoglycan lumican) (KSPG lumican) Lum Lcn Ldc 0.41 −0.12 0.000 0.012
Q8CI59 Metalloreductase STEAP3 (EC 1.16.1.-) (Dudulin-2) (Protein nm1054)
(Six-transmembrane epithelial antigen of prostate 3) (Tumor
suppressor-activated pathway protein 6)
Steap3 Tsap6 0.56 0.84 0.000 0.000
Q01339 Beta-2-glycoprotein 1 (APC inhibitor) (Activated protein C-binding
protein) (Apolipoprotein H) (Apo-H) (Beta-2-glycoprotein I) (B2GPI)
(Beta(2)GPI)
Apoh B2gp1 0.35 0.14 0.000 0.265
P21812 Mast cell protease 4 (mMCP-4) (EC 3.4.21.-) (MSMCP) (Myonase)
(Serosal mast cell protease)
Mcpt4 0.58 −0.27 0.001 0.013
P11087 Collagen alpha-1(I) chain (Alpha-1 type I collagen) Col1a1 Cola1 -0.33 0.65 0.003 0.000
Q9ESB3 Histidine-rich glycoprotein (Histidine-proline-rich glycoprotein) (HPRG) Hrg 0.23 0.11 0.011 0.280
P07758 Alpha-1-antitrypsin 1-1 (AAT) (Alpha-1 protease inhibitor 1)
(Alpha-1-antiproteinase) (Serine protease inhibitor 1-1) (Serine protease
inhibitor A1a) (Serpin A1a)
Serpina1a Dom1 Spi1-1 0.16 0.05 0.013 0.626
Q923B6 Metalloreductase STEAP4 (EC 1.16.1.-) (Dudulin-4)
(Six-transmembrane epithelial antigen of prostate 4) (Tumor necrosis
factor-alpha-induced adipose-related protein)
Steap4 Tiarp 0.42 NA 0.030 NA
Q3UPR9 Somatomedin-B and thrombospondin type-1 domain-containing
protein (RPE-spondin)
Sbspon Gm106 Rpesp 0.17 0.03 0.043 0.717
P27573 Myelin protein P0 (Myelin peripheral protein) (MPP) (Myelin protein zero) Mpz P0 0.42 −0.67 0.044 0.009
P46412 Glutathione peroxidase 3 (GPx-3) (GSHPx-3) (EC 1.11.1.9) (Plasma
glutathione peroxidase) (GPx-P) (GSHPx-P)
Gpx3 0.37 0.00 0.049 0.945
P24526 Myelin P2 protein Pmp2 0.25 −0.54 0.068 0.000
P01872 Ig mu chain C region Ighm Igh-6 0.36 0.85 0.133 0.000
Q8R100 Protein FAM26E Fam26e NA −0.37 NA 0.000
Q9ET38 Claudin-19 Cldn19 0.43 −0.30 0.359 0.001
P47880 Insulin-like growth factor-binding protein 6 (IBP-6) (IGF-binding protein
6) (IGFBP-6)
Igfbp6 Igfbp-6 NA −0.34 NA 0.002
P06909 Complement factor H (Protein beta-1-H) Cfh Hf1 0.20 0.47 0.172 0.004
P51642 Ciliary neurotrophic factor (CNTF) Cntf 0.06 −0.25 0.681 0.005
P82347 Delta-sarcoglycan (Delta-SG) (35 kDa dystrophin-associated
glycoprotein) (35DAG)
Sgcd 0.19 −0.22 0.168 0.009
P50608 Fibromodulin (FM) (Collagen-binding 59 kDa protein) (Keratan sulfate
proteoglycan fibromodulin) (KSPG fibromodulin)
Fmod 0.59 −0.30 0.120 0.011
Q99JA0 Calcitonin gene-related peptide 1 (Alpha-type CGRP) (Calcitonin
gene-related peptide I) (CGRP-I)
Calca Calc 0.02 −0.72 0.928 0.016
P70160 Calcitonin Calca Calc NA −0.72 NA 0.016
Q8BH97 Reticulocalbin-3 Rcn3 D7Ertd671e NA 0.21 NA 0.019
Q99LJ6 Glutathione peroxidase 7 (GPx-7) (GSHPx-7) (EC 1.11.1.9) Gpx7 NA 0.78 NA 0.020
Q61245 Collagen alpha-1(XI) chain Col11a1 -0.12 0.72 0.853 0.028
Q99JF5 Diphosphomevalonate decarboxylase (EC 4.1.1.33) (Mevalonate
(diphospho)decarboxylase) (MDDase) (Mevalonate pyrophosphate
decarboxylase)
Mvd 0.15 −0.23 0.629 0.030
Q9JJH1 Ribonuclease 4 (RNase 4) (EC 3.1.27.-) Rnase4 NA 0.53 NA 0.037
P70271 PDZ and LIM domain protein 4 (LIM protein RIL) (Reversion-induced
LIM protein)
Pdlim4 Ril 0.23 −0.28 0.383 0.048
Q6PFX8 N-acetylaspartylglutamate synthase A (NAAG synthetase A) (NAAGS)
(EC 6.3.2.41) (N-acetylaspartylglutamylglutamate synthase A) (EC
6.3.2.42) (Ribosomal protein S6 modification-like protein A)
Rimkla Fam80a Rimk -0.25 −1.64 0.298 0.049
Graded color code: red, upregulated; green, downregulated; gray, unchanged. Up-and downregulation refer to proteins that were significantly regulated across all three replicates
(Benjamini-Hochberg-corrected p-value, q < 0.05) upon SNI.
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protein, Cancer susceptibility 4 (CASC4), is upregulated during
inflammatory pain. As its name suggests, CASC4 is a proto-
oncogene associated with breast and ovarian cancers (Anczuków
and Krainer, 2015; Anczuków et al., 2015). It has yet to be actively
discussed in the context of pain, but its transcript was found to
be downregulated after spinal nerve transection (http://www.
painnetworks.org:/ SNT_L5vsNAIVE_exonArrays). During
neuropathic pain, galactin-1 (LGALS1) is upregulated. LGALS1
is a widely expressed lectin in a family of proteins implicated in
inflammation, endometriosis, and cancer (Vergetaki et al., 2014).
In the context of pain, it has been shown to mediate the severity
of endometriosis (Vergetaki et al., 2014), as well as potentiate
neuropathic pain in the dorsal horn (Imbe et al., 2003). Similarly,
low-density lipoprotein receptor-related protein (LRP1) is found
to be upregulated upon SNI. LRP1 is a large, multi-ligand
signaling receptor which has been discussed in numerous
contexts, ranging from cancer to oligodendritic cholesterol
homeostasis to ECM remodeling (Etique et al., 2013; Lin et al.,
2017). It has previously been considered as an “injury detection
receptor” in addition to having a role in axonal regeneration
after spinal injury (Yoon et al., 2013). The detection of LRP1
modulation after SNI in this retrospective analysis further hints
at an important role after nerve injury.
Furthermore, we identified five times more proteins which
are regulated in both pain models (55 proteins, previously:
11; Figure 5; complete list: Supplementary Table 10). While
extensive work is needed to assess the functional relevance of
these 55 shared proteins, their regulation in two etiologically
different chronic pain models suggests a role as universal
players in chronic pain. Here, we discuss some examples in
more detail: One notable example is the alpha 2 isoform
of Na+/K+ ATPase (ATP1A2). ATP1A2 is highly expressed
in the brain, and has been implicated in cortical spreading
depression and migraines (Unekawa et al., 2017). In fact,
ATP1A2 represents one of the known susceptibility loci of
familial hemiplegic migraine in humans (Friedrich et al., 2016).
We also found many hits uncharacterized in the context of
chronic pain which may warrant further study. Among them,
we identified 2′,3′-cyclic-nucleotide 3’-phosphodiesterase (CNP),
a myelin protein upregulated in both pain models, which is
highly expressed in oligodendrocytes and Schwann cells (de
Monasterio-Schrader et al., 2012). CNP is thought to play a
role in RNA metabolism (Gravel et al., 2009) and has also
been linked to neuroinflammation in Alzheimer’s disease, Down
Syndrome, and schizophrenia (Barley et al., 2009). Recent work
suggested that its role in axonal support is biased toward
sensory axons in the PNS (http://hdl.handle.net/11858/00-1735-
0000-0023-964D-8) with details remaining to be explored.
Interestingly, the macrophage mannose receptor 1 (MMR or
MRC1) appears to be differentially regulated across both pain
models (CFA down- and SNI upregulated). MMR is a cell surface
receptor involved in host immune responses (Schuette et al.,
2016). It contributes to the suppressive state of macrophages
(Schuette et al., 2016). As such, MMR is upregulated by
interleukin 4 upon nerve injury, which correlates with the
amelioration of behavioral hypersensitivity (Kiguchi et al., 2015).
Its differential regulation in the CFA- and SNI-model likely
reflects its immunomodulatory role inmacrophages and deserves
further investigations.
In contrast to our current study on whole DRG, our
previous work was performed on membrane-enriched DRG
samples (Rouwette et al., 2016). As such, this retrospective
analysis is not exhaustive. Nevertheless, it is highly valuable
for deciphering the regulation of protein levels at membranes
compared to whole-tissue data (the latter reflecting the
overall cellular abundance of proteins). To highlight an
example, several G-protein signaling components (e.g.,
Ras-related proteins: RAB8B RAB4A, RAP1A, RRAS2;
guanine nucleotide-binding protein subunit alpha-13,
GNA13) display changes upon SNI in the DRG membrane
proteome (Supplementary Table 10), which could not be
detected in whole tissue lysates. This suggests that subcellular
FIGURE 5 | Retrospective analysis of DRG membrane proteome dynamics in two chronic pain models. Application of our pan-mouse library for retrospective analysis
of our recently published datasets on mean abundance changes of DRG membrane proteins in the SNI-model of neuropathic pain and the CFA-model of
inflammatory pain (Rouwette et al., 2016). Venn diagram illustrates the proportions of significantly regulated (across all three replicates; Benjamini-Hochberg-corrected
p-value, q < 0.05) DRG membrane proteins. The table lists examples of regulated (+, upregulated; -, downregulated) candidates across both pain models (complete
list: Supplementary Table 10).
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proteome analysis can provide additional and insightful
knowledge about the regulation of proteins during pathological
conditions.
From a technical point of view, we significantly increased the
depth of our previous data using the pan-mouse library generated
here without requiring new tissue samples. This provides a proof-
of-principle to how DIA-MS can open new avenues toward
standardizing and continuously improving proteome data in the
pain community.
A Protein Network Point-of-View on
Neuropathic Pain
Rarely do proteins exert their functions alone. Rather, they are
embedded in protein complexes and larger protein networks
which enable the regulation and plasticity of cellular pathways
(Alberts, 1998; Rouwette et al., 2015). Knowledge of such
protein networks may therefore contribute to a mechanistic
understanding of pathophysiological processes underlying SNI.
This is in line with emerging approaches in network medicine
for modulating diseases (Chapman et al., 2008; Antunes-Martins
et al., 2013; Borsook and Kalso, 2013). We thus inquired whether
significantly regulated proteins upon SNI cluster in distinct
networks and signaling pathways.
Using IPA R© we first broadly determined the interactions
of regulated proteins within known, experimentally verified
networks across all three examined tissues (Krämer A et al.,
2014). Membership of regulated proteins in these networks
is scored based on the in-built Fisher’s exact test by IPA R©
(Supplementary Tables 11–13, which list members of each
network). Besides shared networks, we detected prominent
regional specificity of protein regulation within these networks.
For example, several collagens and integrins implicated in ECM
integrity are co-clustered with others in a network relevant
for dermatological and inflammatory diseases (Network #20,
Supplementary Table 11). Network analysis highlights their
regulation upon SNI in a region-specific manner (Figure 6):
strong upregulation of COL1A1, COL1A2, COL4A1, and
COL4A2 in SN contrasts their downregulation in DRG. They
are unchanged in SC. These data lend further support to the
implication of ECM signaling in PNS processes associated with
SNI.
We additionally critically assessed the possibility that our
data can provide novel network-level insights into the pathology
of proteins already described to be involved in pain. To this
end, we turned to the regulation of several members of the
sodium-potassium ATPase (NKA) family as an example. NKAs
are significantly downregulated in our PNS dataset upon SNI.
Two NKA members, ATP1A1A and ATP1B1, were reported to
set sensory neuron excitability and to be controlled by follistatin-
like protein 1 (FSTL1; Li et al., 2011b). Interestingly, a reduction
of this FSTL1-NKA system in primary afferents correlated
with neuropathic pain behaviors in rodents (Li et al., 2011a).
In line with these findings, we not only observed an overall
downregulation of the FSTL1-NKA system upon SNI, but could
also visualize associated and partially modulated proteins within
the same network in a region-dependent manner (Figure 7).
FIGURE 6 | Region-resolved changes upon SNI in a protein network
implicated in dermatological and inflammatory diseases (Network #20,
Supplementary Table 11). Differential regulation of mean protein abundance
across SN, DRG, and SC becomes apparent and is visualized by a graded
color code. Node color code: red, upregulated; green, downregulated; gray,
unchanged; white, not detected. Predicted relationship among nodes is
indicated by dashed lines. All graphs are created by IPA. Up-and
downregulation refer to proteins that were significantly regulated across all
three replicates (Benjamini-Hochberg-corrected p-value, q < 0.05) upon SNI.
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These include the additional downregulation of several other
NKA family members (A3, B3, and A2) in SN. Moreover, IPA R©
causal analysis (Krämer A et al., 2014) further suggests an
interaction and inhibition of spectrin family members in the PNS
compared to the SC.
We then went on to employ IPA R© to interrogate regulated
proteins associated with canonical cellular pathways. Overall,
we detected changes in diverse pathways, many of which
were differentially modulated in SN compared to DRG or SC
(Figure 8A left). A notable example are interconnected pathways
of mitochondrial dysfunction, oxidative stress response, oxidative
phosphorylation and TCA cycle, known to underlie the diverse
pathology of chronic pain (Baloh, 2008; Akude et al., 2011;
Flatters, 2015). Figure 8A presents a heatmap comparing mean
relative abundance changes of proteins involved inmitochondrial
dysfunction across analyzed regions, with DRG being the most
affected. These results are schematically visualized in Figure 8B.
Importantly, the prominent effect of SNI on mitochondrial
proteins in DRG is in line with our retrospective analysis
of the DRG membrane proteome. This was obtained
from an independent cohort of mice in our previous study
(Supplementary Table 10; Rouwette et al., 2016). Remarkably,
thus, we found differences in the regulation of protein levels
between data from DRG membranes compared to whole DRG.
In DRG membrane samples we measured an upregulation of
many proteins belonging to the mitochondrial respiratory chain
(e.g., NDUFV1, NDUFS4, NDUFS5, NDUFA5, and NDUFS3;
Supplementary Table 10) in contrast to their downregulation in
whole DRG (Supplementary Table 8). These data may provide
valuable insights into subcompartmental regulation, particularly
regarding mitochondria. Ninety-nine percent of mitochondrial
proteins are encoded by nuclear genes, thus their synthesis
at cytosolic ribosomes, their cytosolic abundance, and their
subsequent import into mitochondria are crucial for organelle
function (Schmidt et al., 2010; Wiedemann and Pfanner, 2017).
Protein import occurs in response to a variety of conditions,
including oxidative stress, and is considered to contribute
to mitochondrial dysfunction associated with diverse human
diseases (MacKenzie and Payne, 2007). Currently, we can only
speculate as to how here detected abundance changes may affect
mitochondrial dysfunction. Nonetheless, our data build on
previous work to suggest defects in mitochondrial import and
membrane assembly play a role in neuropathic pain.
DISCUSSION
To obtain a thorough understanding of chronic pain, system
wide mapping of the pain axis at the protein level is necessary.
This has not yet been achieved. This is largely due to the fact
that the technology required to reproducibly and quantitatively
compare proteomes has emerged only recently. Here, we built
upon these technical advances and offer a comprehensive protein
compendium of three regions at the beginning of the pain
neuraxis—the SN, DRG, and SC. Our results yield unprecedented
insights into the proteome composition of these regions and their
dynamics during neuropathic pain. We further provide a thus far
FIGURE 7 | Region-resolved changes in the FSTL1-NKA-protein network
upon SNI. Differential regulation of mean protein abundance across SN, DRG,
and SC becomes apparent and is visualized by a graded color code. Node
color code: red, upregulated; green, downregulated; gray, unchanged; white,
not detected. Moreover, causal network analysis predicts differences in
activation (line color orange) and inhibition (line color blue) of distinct
connections between members of this network. Predicted relationship among
nodes is indicated by dashed lines. All graphs are created by IPA. Up-and
downregulation refer to proteins that were significantly regulated across all
three replicates (Benjamini-Hochberg-corrected p-value, q < 0.05) upon SNI.
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FIGURE 8 | Region-resolved regulation of canonical pathways upon SNI. (A) Left, annotation matrix of pathway enrichment analysis for proteins regulated across all
three replicates upon SNI in SN, DRG, and SC (scored based on the in-built Fisher’s exact test by IPA using the –log10 p-value). Right, heatmap depicts mean
abundance changes (log2 fold change SNI/Sham; across all three replicates) of regulated proteins implicated in “mitochondrial dysfunction.” Color code: red,
upregulated; green, downregulated; gray, unchanged; white, not detected. (B) Schematic representation and comparison of differentially regulated proteins in the
electron transport chain (DRG versus SN). Mean protein abundance changes of significantly regulated proteins across all replicates are coded by a color gradient.
Color code: red, upregulated; green, downregulated; gray, unchanged; white, not detected. All matrices and graphs are created by IPA. Up-and downregulation refer
to proteins that were significantly regulated across all three replicates (Benjamini-Hochberg-corrected p-value, q < 0.05) upon SNI.
unique dataset on proteins and protein networks that are highly
enriched in the PNS and SC. Consequently, our study fills an
eminent gap in the pain field and serves as a stepping stone for
defining protein disease signatures and novel therapeutic targets
of chronic pain.
Chronic pain is an extremely complex disease involving a
myriad of molecular changes (Costigan et al., 2009; Patapoutian
et al., 2009; Sommer, 2016; Price and Gold, 2017). This is likely
why treatments interfering with single proteins exhibit only
limited efficacy. Emerging medical research initiatives aim for a
“mechanism-based” approach toward pain therapy (Borsook and
Kalso, 2013; Gilron et al., 2013; Treede et al., 2013; Sommer,
2016; Vardeh et al., 2016; Baron et al., 2017). A prerequisite for
this is a thorough, systems biology understanding of the complex
and dynamic molecular interplay contributing to chronic pain
(Chapman et al., 2008; Antunes-Martins et al., 2013; Borsook and
Kalso, 2013).
Extensive genomic (Diatchenko et al., 2005, 2007, 2013;
Sorge et al., 2012; Zorina-Lichtenwalter et al., 2016), epigenomic
(Doehring et al., 2011; Denk and McMahon, 2012; Niederberger,
2014), and transcriptomic studies (Grace et al., 2012; Simonetti
et al., 2013; Jeong et al., 2016) have provided highly valuable
insights into the changes associated with painful pathologies
in rodents and patients. Nonetheless, their predictability of
phenotypes is limited (Mogil, 2012; Geyer et al., 2016; Liu et al.,
2016; Sommer, 2016). This is especially the case for transient
and/or dynamic biological processes, given the existence of
various cellular buffering mechanisms (Liu et al., 2016). In
contrast, the proteome constitutes a highly valuable source of
molecular information for monitoring phenotypes - including
disease onset and progression (Chen et al., 2015; Ebhardt et al.,
2015; Sajic et al., 2015; Gazerani and Vinterhoj, 2016; Geyer
et al., 2016, 2017). This advantage of standardized proteome
analysis is extensively exploited in oncological research to
define robust molecular tumor signatures (Hüttenhain et al.,
2012; Cerciello et al., 2013; Takadate et al., 2013). Thus
far, similar system-wide studies are lacking in the context
of pain. In the pain field, most work published relies on
gel-based approaches (typically 2D-PAGE) followed by data-
dependent acquisition mass spectrometry (DDA-MS), often
referred to as shotgun proteomics (Domon and Aebersold,
2010; Michalski et al., 2011). These methods have laid the
foundation for proteomic studies of chronic pain (Huang et al.,
2008; Olausson et al., 2012, 2015; Vacca et al., 2014). They
are also known for their limitations regarding biased sampling,
protein losses, and low reproducibility between studies (Domon
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and Aebersold, 2010; Michalski et al., 2011). Emerging data-
independent acquisition mass spectrometry (DIA-MS; Venable
et al., 2004; Panchaud et al., 2009; Carvalho et al., 2010)
helps to overcome some of these limitations. In essence, DIA-
MS enables the identification and quantification of proteins
on a large scale and in a standardized and reproducible
manner (Domon and Aebersold, 2010; Sajic et al., 2015).
Therefore, it is ideally suited to interrogate pathology-related
proteome changes (Hüttenhain et al., 2012; Cerciello et al.,
2013).
Using DIA-MS, our previous study on the membrane
proteome of DRG provided a glimpse of differential and pain-
model specific changes in distinct cellular protein networks
(Rouwette et al., 2016). Here, we extended our previous study
and monitored global proteome changes in the SN, DRG, and
SC. A wealth of previous work has shown that the PNS is
(i) a significant driver of chronic pain, and (ii) offers higher
therapeutic accessibility than brain areas implicated in pain
(Puljak et al., 2009; Liem et al., 2013; Krames, 2014; Berta
et al., 2017b). Consequently, recent therapeutic strategies aim
to selectively target peripheral sensory neurons for pain relief
(Sapunar et al., 2012; Liem et al., 2013; Haroutounian et al., 2014;
Krames, 2014; Berta et al., 2017b). Despite its apparent clinical
importance, the protein composition of the PNS has not been
thoroughly investigated. Our study fills this gap and defines for
the first time a set of PNS-enriched proteins in reference to
two independent but highly similar and large-scale datasets of
the mouse brain (our own results and results of others; Sharma
et al., 2015). In addition, we cross-correlated these data with the
Human Protein Atlas harboring protein information on more
than 30 human tissues. This enabled us to define PNS-enriched
protein signatures with high utility for translational research.
Strikingly, 32 of these putative PNS-enriched candidate
proteins in humans displayed significant regulation in the
SNI-model (Table 2). Among these, several are implicated in
ECM integrity. The ECM is crucial for signal transduction
and communication between extra- and intracellular spaces
(Manninen and Varjosalo, 2017). Additionally, it is modulated
in response to diverse stimuli. The ECM has been implicated in
tissue homeostasis, as well as pathological processes triggered by
nerve injury in the SC (Bartus et al., 2014; Tajerian and Clark,
2015). In chronic pain conditions, there is accumulating evidence
for the role of ECM changes in hypersensitivity and long lasting
maladaptation, particularly by affecting synaptic plasticity in the
CNS (Tajerian and Clark, 2015). Yet, details about the role of
its protein constituents for PNS (patho-) physiology remain to
be investigated. Here, we reveal pronounced abundance changes
of distinct proteins implicated in ECM integrity in our DRG
and SN datasets. Collectively, these findings strongly suggest the
involvement of ECM signaling in processes associated with SNI,
and may warrant detailed studies on here identified regulated
candidates.
Another notable feature of observed SNI-induced dynamics
within the PNS is the high representation of proteins involved
in immune signaling and inflammation (Figure 4 and
Supplementary Table 8). This is in line with the evolving notion
that DRG and SN harbor diverse immune cells (e.g., macrophages
and T cells) with critical functions for normal physiology and
during chronic pain (Krames, 2014; Ji et al., 2016; Sommer, 2016;
Price and Gold, 2017; Cobos et al., 2018). In fact, a recent study
demonstrated mechanistic differences in the contribution of
immune cells to SNI-induced phenotypes: While they are largely
dispensable for cold allodynia, immune cells appear to be critical
for the development of tactile hypersensitivity likely via their
interplay with sensory neurons (Cobos et al., 2018). Interestingly,
our data reveal a significant overrepresentation of proteins
associated with IPA R© pathways of acute phase response signaling
and chronic inflammatory disorders in PNS-enriched proteomes
(Supplementary Table 3). Many of these are regulated upon SNI
(e.g., diverse SERPINS; Figure 4 and Supplementary Table 8)
and associated with other regulated proteins in distinct
protein networks (Figure 6 and Supplementary Tables 11–13).
Moreover, our retrospective analysis finds similarities in protein
regulation during neuropathic and inflammatory pain (e.g., CNP,
ATP1A2, NOMO1; Figure 5 and Supplementary Table 10).
Hence, we uncover candidates for mechanistic follow-up studies
on their role for immune and inflammatory signaling in the
SNI-model.
Furthermore, we observe marked alterations in canonical
pathways related to mitochondrial dysfunction (Figure 8). The
importance of mitochondria in chronic pain is increasingly
recognized (Baloh, 2008; Akude et al., 2011; Flatters, 2015). Our
data extend existing knowledge by providing unprecedented
and region-resolved details about alterations in specific
mitochondrial proteins during chronic pain, particularly in the
PNS. Interestingly, a recent transcriptome study showed that
specifically injured neurons activate oxidative stress responses as
early as 7 days after SNI (Berta et al., 2017a) suggesting that in
our study a substantial part of observed changes may be derived
from injured neurons.
In summary, we report here pronounced and differential
dynamics upon SNI by looking at the proteome. On one
hand, this knowledge will contribute to our understanding of
diverse (patho-) physiological processes underlying the SNI-
model (Decosterd and Woolf, 2000): not only chronic pain,
but also tissue injury, activation of immune cells, and nerve
de-/regeneration. On the other hand, our findings open
opportunities for targeting regulated proteins and associated
protein networks in treatments of chronic pain.
Of note, in order to reduce the number of mice and samples
needed for this study in observation of the 3 Rs of animal research,
we used mice 28 days after Sham-surgery as controls to define
tissue-resolved proteomes. While we cannot exclude proteome
changes induced by Sham-surgery lasting for 28 days thereafter,
several of our findings support the idea that our region-resolved
proteomes largely reflect their “normal” protein content: (i) the
here identified brain proteome is highly similar to previously
published data in mice (Sharma et al., 2015), and (ii) the here
identified PNS, SC proteomes, and region-enriched proteomes
are in high accordance with legacy data on the molecular-set up
of these tissues (Figure 3).
A common concern of tissue-based proteomics (and
transcriptomics alike) experiments is the mixture of different
cell types contained in each tissue. Therefore, the identified
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proteome alterations may be contributed by any cell type of
the studied tissue. Further, changes of a distinct protein in one
cell population may be masked by opposing changes in others.
For example, our results in DRG likely reflect the proteome
of diverse subpopulations of sensory neurons (Usoskin et al.,
2015), immune cells, glia cells, and endothelial cells, many of
which with prominent roles in painful pathologies (Krames,
2014; Ji et al., 2016; Sommer, 2016; Price and Gold, 2017). At
this point we cannot judge the relative contributions of cell
types to our DRG datasets; however, a comparison with existing
transcriptome data of purified nociceptors (Thakur et al., 2014)
and DRG subpopulations (Usoskin et al., 2015) enabled us to
roughly estimate the proportion of neuronally expressed proteins
to ∼50%. These included known hallmark proteins of sensory
DRG neurons, such as distinct ion channels and their interaction
partners.
Another problem of tissue-based -omics arises from the
intermingling of injured (dissected) and uninjured neurons in
DRG and SN upon SNI. Moreover, fibers which were not
primarily injured by the SNI surgery have been shown to be
affected as well, exhibiting ectopic firing and contributing to
the pathology (Costigan et al., 2009; Berta et al., 2017a). Recent
transcriptome studies have elegantly compared injured with
uninjured fibers (Hu et al., 2016; Berta et al., 2017a). Interestingly,
it appears that such changes extend far beyond transcriptional
regulation and need to be analyzed on the protein level, as well
(Hu et al., 2016; Berta et al., 2017a).
Hence, future efforts should focus on efficiently labeling
neuronal subpopulations in vivo. This would enable their
separation followed by differential proteome analysis. Ideally,
one would like to analyze single cell populations. So far, the
analysis of single cell types is not amenable to comprehensive
proteome profiling due to restrictions in sample amount and
known limitations of profiling low abundant proteins in complex
samples. Mass spectrometry workflows are rapidly evolving to
improve both sensitivity and reproducibility. These advances
involve novel acquisition strategies and computational analysis
tools to maximize the amount of protein information obtained
(Schubert et al., 2015; Tsou et al., 2015; Geyer et al., 2016;
Bruderer et al., 2017a,b), all of which will open new possibilities
in comprehensive proteome profiling of chronic pain.
Overall, we reveal dynamic changes of distinct
protein networks during chronic pain (Figure 6 and
Supplementary Tables 11–13; Figures 7, 8). This is highly
relevant for state-of-the-art strategies in finding novel
drug targets. As mentioned, therapeutic strategies targeting
single proteins lack efficiency and often—depending on their
organismal role—specificity to chronic pain (Borsook et al.,
2014). The system-wide identification of critical hubs within
defined protein networks, however, holds the promising potential
to generate combinatorial therapeutic interventions, ideally less
likely to cause severe side effects (Chapman et al., 2008; Barabási
et al., 2011; Antunes-Martins et al., 2013; Borsook and Kalso,
2013; Chen et al., 2015). In order to promote a systems view
on pain, Perkins and colleagues implemented “PainNetworks”
(Perkins et al., 2013), Jamieson and colleagues summarized the
“pain interactome” (Jamieson et al., 2014) and recent studies
systematically mapped the DRG/PNS-enriched transcriptome by
contrasting it to body-wide gene expression (Sapio et al., 2016;
Ray et al., 2018). We now complement these efforts and provide a
freely-available and searchable database (painproteome.em.mpg.
de) harboring all data described in this work, i.e., region-resolved
proteomes as well as SNI-associated proteome changes. In
addition to encouraging future experimental investigations,
these data may be used to test the application of designated
network theory algorithms to find disease modules in large
datasets (Zhang et al., 2009; Barabási et al., 2011; Shi et al., 2015;
Kitsak et al., 2016). Examples of network theory impact include
insightful work on cardiovascular diseases, cancer, and diabetes
summarized elsewhere (Oti et al., 2006; Barabási et al., 2011;
Zhou et al., 2014; Kitsak et al., 2016).
In conclusion, we have shown that the analysis of proteins
and protein networks can promote novel insights into disease
features of chronic pain. This may facilitate the development
of mechanism-based therapies, which are urgently required for
chronic pain syndromes (Gereau et al., 2014; Baron et al., 2017).
We are confident that the pain community will quickly integrate
such a protein-centric and systems-inspired view. To expedite
this process, we comprehensively characterized the proteome
and its pathology-associated dynamics along the beginning of
the pain axis. Our results provide the necessary foundation for
future studies examining the protein signature of chronic pain
syndromes in different regions and in time.
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Supplementary Figure 1 | Quantification of unilateral (ipsilateral, ipsi) mechanical
allodynia induced by SNI. The graph depicts average withdrawal latencies to
innocuous mechanical stimulation of ipsi- and contralateral (contra, untreated
control) paws before (pre) and 4 weeks (4 wk) after Sham and SNI-surgery,
respectively. Mechanical allodynia is only observed 4 weeks after surgery in
SNI-treated animals as indicated by a reduction of the withdrawal thresholds of
ipsi paws compared to contra paws (N = 12 animals per condition). One-way
ANOVA followed by Holm-Sidak’s multiple comparison test, ∗∗∗∗p < 0.0001 of
corresponding ipsi vs. contra paws of SNI-treated animals.
Supplementary Figure 2 | Regression analysis across Sham sample replicates.
Sham replicates (control, C1-C3) are plotted per tissue, with scatter plots and
Pearson’s correlation coefficient shown per interaction. Protein intensity
distributions (per replicate) are shown on the diagonal as kernel density estimates.
Supplementary Figure 3 | Representation of gene products (top 50) of indicated
sensory neuron subpopulations published by Usoskin et al. (2015) in our DRG
proteome of Sham mice.
Supplementary Figure 4 | DIA-MS: comparison of Sham with SNI samples. (A)
Unsupervised clustering of z-scored normalized protein intensities from all
replicates of SN, DRG, and SC tissue across SNI (pain, P1-P3) and Sham (control,
C1-C3) replicates. The difference of replicate C2_DRG to other DRG samples is
unexpected and likely explained by variability in sample preparation. Different
colors of the y-axis dendrogram visualize exemplary clusters of proteins. (B)
Regression analysis across SNI (pain, P1-P3) and Sham (control, C1-C3)
replicates. Replicates are plotted per tissue (SN, DRG, and SC) with Pearson’s
correlation coefficient shown for each interaction.
Supplementary Table 1 | The pan-mouse library.
Supplementary Table 2 | DIA-MS results of proteins identified in tissues of Sham
mice.
Supplementary Table 3 | Pathway analysis in tissues of Sham mice.
Supplementary Table 4 | List of proteins enriched in the PNS of Sham mice
compared to brain areas.
Supplementary Table 5 | List of proteins enriched in the SC of Sham mice
compared to brain areas.
Supplementary Table 6 | Comparisons of published studies with our PNS
proteome, PNS-enriched proteome, SC proteome, and SC-enriched proteome.
Supplementary Table 7 | Comparisons of our data to PGD, HPGDB and
conserved DRG-enriched transcripts.
Supplementary Table 8 | Proteins significantly regulated upon SNI within the
PNS proteome, PNS-enriched proteome, SC proteome, and SC-enriched
proteome.
Supplementary Table 9 | Comparisons of published studies with proteins
significantly regulated upon SNI within the PNS proteome and the PNS-enriched
proteome.
Supplementary Table 10 | Retrospective analysis of data on the DRG membrane
proteome previously published by our laboratory.
Supplementary Table 11 | Top biological networks harboring DRG proteins
significantly regulated upon SNI.
Supplementary Table 12 | Top biological networks harboring SN proteins
significantly regulated upon SNI.
Supplementary Table 13 | Top biological networks harboring SC proteins
significantly regulated upon SNI.
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